USRE44338E1 - Amyloid plaque aggregation inhibitors and diagnostic imaging agents - Google Patents
Amyloid plaque aggregation inhibitors and diagnostic imaging agents Download PDFInfo
- Publication number
- USRE44338E1 USRE44338E1 US13/550,853 US201213550853A USRE44338E US RE44338 E1 USRE44338 E1 US RE44338E1 US 201213550853 A US201213550853 A US 201213550853A US RE44338 E USRE44338 E US RE44338E
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- compounds
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 0 [1*]N([2*])C1=CC=C(c2[y]c3cc([3*])ccc3n2C)C=C1 Chemical compound [1*]N([2*])C1=CC=C(c2[y]c3cc([3*])ccc3n2C)C=C1 0.000 description 7
- UJYDERAWUKCOHC-UHFFFAOYSA-L B.BrBr.CC1=CC=C2C(=C1)N=C(C1=CC=C(N(C)C)C=C1)N2C.CC1=CC=C2C(=C1)N=C(C1=CC=C(N(C)C)C=C1)N2C.CN(C)C1=CC=C(C2=NC3=CC(Br)=CC=C3N2C)C=C1.CNC1=CC=C(Br)C=C1N.CNC1=CC=C(Br)C=C1[N+](=O)[O-].CNC1=CC=CC=C1[N+](=O)[O-].CO.COC1=CC=C(N(C)C)C=C1.Cl[Sn]Cl.NC1=CC=CC=C1[N+](=O)[O-].[NaH] Chemical compound B.BrBr.CC1=CC=C2C(=C1)N=C(C1=CC=C(N(C)C)C=C1)N2C.CC1=CC=C2C(=C1)N=C(C1=CC=C(N(C)C)C=C1)N2C.CN(C)C1=CC=C(C2=NC3=CC(Br)=CC=C3N2C)C=C1.CNC1=CC=C(Br)C=C1N.CNC1=CC=C(Br)C=C1[N+](=O)[O-].CNC1=CC=CC=C1[N+](=O)[O-].CO.COC1=CC=C(N(C)C)C=C1.Cl[Sn]Cl.NC1=CC=CC=C1[N+](=O)[O-].[NaH] UJYDERAWUKCOHC-UHFFFAOYSA-L 0.000 description 1
- AKWBPFAYHBGNKL-UHFFFAOYSA-N B.C1CCOC1.C1CCOC1.CC(C)O.CN(C)C1=CC=C(C2=NC3=CC=C(Br)C=C3C=N2)C=C1.COC1=CC=C(N(C)C)C=C1.N.NC(=O)C1=CC(Br)=CC=C1N.NCC1=CC(Br)=CC=C1N.O.O=C1CC2=CC=C(Br)C=C2C(=O)O1 Chemical compound B.C1CCOC1.C1CCOC1.CC(C)O.CN(C)C1=CC=C(C2=NC3=CC=C(Br)C=C3C=N2)C=C1.COC1=CC=C(N(C)C)C=C1.N.NC(=O)C1=CC(Br)=CC=C1N.NCC1=CC(Br)=CC=C1N.O.O=C1CC2=CC=C(Br)C=C2C(=O)O1 AKWBPFAYHBGNKL-UHFFFAOYSA-N 0.000 description 1
- PKKBYNAOYPFVFO-UHFFFAOYSA-N BrC1=CC=C2N=C(C3=CC=C(I)C=C3)N=CC2=C1.C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CNC1=CC=C(C2=NC3=CC=C(Br)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(C)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(I)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(I)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(I)C=C3C=N2)C=C1.COC1=CC=C(I)C=C1.NCC1=CC(Br)=CC=C1N Chemical compound BrC1=CC=C2N=C(C3=CC=C(I)C=C3)N=CC2=C1.C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CNC1=CC=C(C2=NC3=CC=C(Br)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(C)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(I)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(I)C=C3C=N2)C=C1.CNC1=CC=C(C2=NC3=CC=C(I)C=C3C=N2)C=C1.COC1=CC=C(I)C=C1.NCC1=CC(Br)=CC=C1N PKKBYNAOYPFVFO-UHFFFAOYSA-N 0.000 description 1
- SYSXXJQGWJKNEK-UHFFFAOYSA-N BrC1=CC=C2N=C(C3=CC=C(I)C=C3)SC2=C1.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CN(C)C1=CC=C(C2=NC3=C(C=C(I)C=C3)S2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(Br)C=C3)S2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(C)C=C3)S2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)S2)C=C1.NC1=CC=C(Br)C=C1S.O=COC1=CC=C(I)C=C1 Chemical compound BrC1=CC=C2N=C(C3=CC=C(I)C=C3)SC2=C1.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CN(C)C1=CC=C(C2=NC3=C(C=C(I)C=C3)S2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(Br)C=C3)S2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(C)C=C3)S2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)S2)C=C1.NC1=CC=C(Br)C=C1S.O=COC1=CC=C(I)C=C1 SYSXXJQGWJKNEK-UHFFFAOYSA-N 0.000 description 1
- RDMCPIONFWJPEO-UHFFFAOYSA-N BrC1=CN2C=C(C3=CC=C(I)C=C3)N=C2C=C1.C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CN(C)C1=CC=C(C2=CN3C=C(I)C=CC3=N2)C=C1.CNC1=CC=C(C2=CN3C=C(Br)C=CC3=N2)C=C1.CNC1=CC=C(C2=CN3C=C(C)C=CC3=N2)C=C1.CNC1=CC=C(C2=CN3C=C(I)C=CC3=N2)C=C1.NC1=NC=C(Br)C=C1.O=C(CBr)C1=CC=C(I)C=C1 Chemical compound BrC1=CN2C=C(C3=CC=C(I)C=C3)N=C2C=C1.C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CN(C)C1=CC=C(C2=CN3C=C(I)C=CC3=N2)C=C1.CNC1=CC=C(C2=CN3C=C(Br)C=CC3=N2)C=C1.CNC1=CC=C(C2=CN3C=C(C)C=CC3=N2)C=C1.CNC1=CC=C(C2=CN3C=C(I)C=CC3=N2)C=C1.NC1=NC=C(Br)C=C1.O=C(CBr)C1=CC=C(I)C=C1 RDMCPIONFWJPEO-UHFFFAOYSA-N 0.000 description 1
- JHXZVSDIEKTYJO-UHFFFAOYSA-M C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN(C)C1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(Br)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(C)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(N)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C([N+](=O)[O-])C=C3)O2)C=C1.CNC1=CC=C(OC=O)C=C1.NC1=C(O)C=C([N+](=O)[O-])C=C1.[K]Br Chemical compound C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN(C)C1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(Br)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(C)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(N)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C([N+](=O)[O-])C=C3)O2)C=C1.CNC1=CC=C(OC=O)C=C1.NC1=C(O)C=C([N+](=O)[O-])C=C1.[K]Br JHXZVSDIEKTYJO-UHFFFAOYSA-M 0.000 description 1
- JPOZFVQGCDMPKW-UHFFFAOYSA-N C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CN(C)C1=CC=C(C2=NC3=CC(I)=CC=C3N2C)C=C1.CN1C2=CC=C(Br)C=C2N=C1C1=CC=C(I)C=C1.CNC1=CC=C(Br)C=C1N.CNC1=CC=C(C2=NC3=CC(Br)=CC=C3N2C)C=C1.CNC1=CC=C(C2=NC3=CC(C)=CC=C3N2C)C=C1.CNC1=CC=C(C2=NC3=CC(I)=CC=C3N2C)C=C1.COC1=CC=C(I)C=C1 Chemical compound C.C.C.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CN.CN(C)C1=CC=C(C2=NC3=CC(I)=CC=C3N2C)C=C1.CN1C2=CC=C(Br)C=C2N=C1C1=CC=C(I)C=C1.CNC1=CC=C(Br)C=C1N.CNC1=CC=C(C2=NC3=CC(Br)=CC=C3N2C)C=C1.CNC1=CC=C(C2=NC3=CC(C)=CC=C3N2C)C=C1.CNC1=CC=C(C2=NC3=CC(I)=CC=C3N2C)C=C1.COC1=CC=C(I)C=C1 JPOZFVQGCDMPKW-UHFFFAOYSA-N 0.000 description 1
- YMGKXCDJGSFICU-UOTZVPAXSA-N C.CC1=CC2=C(C=C1)C=C(C1=CC=C(N(C)C)C=C1)N2C.CC1=CC=C(Br)C=C1[N+](=O)[O-].CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CCOC(C)N(C)C.CN(C)/C=C(\C(=O)C1=CC=C(N(C)C)C=C1)C1=CC=C(Br)C=C1[N+](=O)[O-].CN(C)/C=C/C1=CC=C(Br)C=C1[N+](=O)[O-].CN(C)C1=CC=C(C(=O)CC2=C([N+](=O)[O-])C=C(Br)C=C2)C=C1.CN(C)C1=CC=C(C(=O)Cl)C=C1.CN(C)C1=CC=C(C2=CC3=C(C=C(Br)C=C3)N2)C=C1.CN(C)C1=CC=C(C2=CC3=C(C=C(Br)C=C3)N2C)C=C1.CN(C)C1=CC=C(C2=CC3=C(C=C(I)C=C3)N2C)C=C1.O=S(=O)=S(=O)=O.[2H]CF.[Na][Na] Chemical compound C.CC1=CC2=C(C=C1)C=C(C1=CC=C(N(C)C)C=C1)N2C.CC1=CC=C(Br)C=C1[N+](=O)[O-].CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CCOC(C)N(C)C.CN(C)/C=C(\C(=O)C1=CC=C(N(C)C)C=C1)C1=CC=C(Br)C=C1[N+](=O)[O-].CN(C)/C=C/C1=CC=C(Br)C=C1[N+](=O)[O-].CN(C)C1=CC=C(C(=O)CC2=C([N+](=O)[O-])C=C(Br)C=C2)C=C1.CN(C)C1=CC=C(C(=O)Cl)C=C1.CN(C)C1=CC=C(C2=CC3=C(C=C(Br)C=C3)N2)C=C1.CN(C)C1=CC=C(C2=CC3=C(C=C(Br)C=C3)N2C)C=C1.CN(C)C1=CC=C(C2=CC3=C(C=C(I)C=C3)N2C)C=C1.O=S(=O)=S(=O)=O.[2H]CF.[Na][Na] YMGKXCDJGSFICU-UOTZVPAXSA-N 0.000 description 1
- AZHYTCWKXOTZHQ-UHFFFAOYSA-N C.CC1=CC=C2N=C(C3=CC=C(N(C)C)C=C3)SC2=C1.CN(C)C1=CC=C(C2=NC3=CC=C(Br)C=C3S2)C=C1.CN(C)C1=CC=C(C2=NC3=CC=C(I)C=C3S2)C=C1.COC1=CC=C(N(C)C)C=C1.NC1=CC=C(Br)C=C1.NC1=CC=C(Br)C=C1S.NC1=NC2=CC=C(Br)C=C2S1 Chemical compound C.CC1=CC=C2N=C(C3=CC=C(N(C)C)C=C3)SC2=C1.CN(C)C1=CC=C(C2=NC3=CC=C(Br)C=C3S2)C=C1.CN(C)C1=CC=C(C2=NC3=CC=C(I)C=C3S2)C=C1.COC1=CC=C(N(C)C)C=C1.NC1=CC=C(Br)C=C1.NC1=CC=C(Br)C=C1S.NC1=NC2=CC=C(Br)C=C2S1 AZHYTCWKXOTZHQ-UHFFFAOYSA-N 0.000 description 1
- PZXPVHNXWHGVFN-UHFFFAOYSA-N C.CC1=CC=C2N=C(C3=CC=C(N4CCN(C)CC4)C=C3)SC2=C1.CN1CCC(N)CC1.CN1CCN(C2=CC=C(C3=NC4=CC=C(Br)C=C4S3)C=C2)CC1.CN1CCN(C2=CC=C(C3=NC4=CC=C(I)C=C4S3)C=C2)CC1.COC1=CC=C(N2CCN(C)CC2)C=C1.NC1=CC=C(Br)C=C1S.O=CC1=CC=C(F)C=C1 Chemical compound C.CC1=CC=C2N=C(C3=CC=C(N4CCN(C)CC4)C=C3)SC2=C1.CN1CCC(N)CC1.CN1CCN(C2=CC=C(C3=NC4=CC=C(Br)C=C4S3)C=C2)CC1.CN1CCN(C2=CC=C(C3=NC4=CC=C(I)C=C4S3)C=C2)CC1.COC1=CC=C(N2CCN(C)CC2)C=C1.NC1=CC=C(Br)C=C1S.O=CC1=CC=C(F)C=C1 PZXPVHNXWHGVFN-UHFFFAOYSA-N 0.000 description 1
- UPWRHIVUOIAVHO-UHFFFAOYSA-N C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CCN(CC)CC.CCN(CC)CC.CN(C)C1=CC=C(C2=CC3=CC(Br)=CC=C3O2)C=C1.CN(C)C1=CC=C(C2=CC3=CC=C(Br)C=C3O2)C=C1.COC1=CC=C(N(C)C)C=C1.COC1=CC=C(N(C)C)C=C1.OC1=CC(Br)=CC=C1CCl.OC1=CC(N2/N=N\C3=CC=CC=C32)=CC=C1CP(Cl)(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.OC1=CC=C(Br)C=C1CCl.OC1=CC=C(Br)C=C1CP(Cl)(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CCN(CC)CC.CCN(CC)CC.CN(C)C1=CC=C(C2=CC3=CC(Br)=CC=C3O2)C=C1.CN(C)C1=CC=C(C2=CC3=CC=C(Br)C=C3O2)C=C1.COC1=CC=C(N(C)C)C=C1.COC1=CC=C(N(C)C)C=C1.OC1=CC(Br)=CC=C1CCl.OC1=CC(N2/N=N\C3=CC=CC=C32)=CC=C1CP(Cl)(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.OC1=CC=C(Br)C=C1CCl.OC1=CC=C(Br)C=C1CP(Cl)(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 UPWRHIVUOIAVHO-UHFFFAOYSA-N 0.000 description 1
- YCMGGDAJASEYOQ-UHFFFAOYSA-L C=C1CS[Tc]23(=O)SCCN2(C(C)C)CCN13 Chemical compound C=C1CS[Tc]23(=O)SCCN2(C(C)C)CCN13 YCMGGDAJASEYOQ-UHFFFAOYSA-L 0.000 description 1
- OWBUTCAZKDYPII-VCCCQOPFSA-F C=C1CS[Tc]23(=O)SCCN2(C(C)C)CCN13.CC(C)N12CCS[Tc]13(=O)SCCN3CC2.CC(C)N1CC[C@@H]2[C@@H](CC1)N1CCS[Tc]13(=O)SCCN23.CC(C)N1C[C@@H]2[C@@H](C1)N1CCS[Tc]13(=O)SCCN23 Chemical compound C=C1CS[Tc]23(=O)SCCN2(C(C)C)CCN13.CC(C)N12CCS[Tc]13(=O)SCCN3CC2.CC(C)N1CC[C@@H]2[C@@H](CC1)N1CCS[Tc]13(=O)SCCN23.CC(C)N1C[C@@H]2[C@@H](C1)N1CCS[Tc]13(=O)SCCN23 OWBUTCAZKDYPII-VCCCQOPFSA-F 0.000 description 1
- ZYCHTLWLZIXETO-UHFFFAOYSA-N CB(O)N(C)C1=CC=C(C2=CC3=CC=C(Br)C=C3O2)C=C1.CB(O)N(C)C1=CC=C(C2=CC3=CC=C(C)C=C3O2)C=C1.CB(O)N(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1.CB(O)N(C)C1=CC=C(CCl)C=C1.CB(O)N(C)C1=CC=C(COC2=CC(Br)=CC=C2C=O)C=C1.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CCO.CN(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1.II.O=CC1=CC=C(Br)C=C1O.O[Na].[H+].[H]N(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1 Chemical compound CB(O)N(C)C1=CC=C(C2=CC3=CC=C(Br)C=C3O2)C=C1.CB(O)N(C)C1=CC=C(C2=CC3=CC=C(C)C=C3O2)C=C1.CB(O)N(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1.CB(O)N(C)C1=CC=C(CCl)C=C1.CB(O)N(C)C1=CC=C(COC2=CC(Br)=CC=C2C=O)C=C1.CCC1=CC=C(F)C=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CCO.CN(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1.II.O=CC1=CC=C(Br)C=C1O.O[Na].[H+].[H]N(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1 ZYCHTLWLZIXETO-UHFFFAOYSA-N 0.000 description 1
- NHEZUBBPVWRQDJ-PXMQHIJYSA-N CC(=O)C1=CC=C(N(C)C)C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN=C(N)C=C1.CCN(CC)CC.CCOP(O)OCC.CN(C)C1=CC=C(C(=O)C(Br)Br)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CN(C)C1=CC=C(C2=CN3C=C([125I])C=CC3=N2)C=C1 Chemical compound CC(=O)C1=CC=C(N(C)C)C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN=C(N)C=C1.CCN(CC)CC.CCOP(O)OCC.CN(C)C1=CC=C(C(=O)C(Br)Br)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CN(C)C1=CC=C(C2=CN3C=C([125I])C=CC3=N2)C=C1 NHEZUBBPVWRQDJ-PXMQHIJYSA-N 0.000 description 1
- RKAOIJPELGTBGE-VCCCQOPFSA-E CC(C)N12CCS[Tc]13(=O)SCC(=O)N3CC2.CC(C)N12CCS[Tc]13(=O)SCCN3CC2.CC(C)N1CC[C@@H]2[C@@H](CC1)N1CCS[Tc]13(=O)SCCN23.CC(C)N1C[C@@H]2[C@@H](C1)N1CCS[Tc]13(=O)SCCN23 Chemical compound CC(C)N12CCS[Tc]13(=O)SCC(=O)N3CC2.CC(C)N12CCS[Tc]13(=O)SCCN3CC2.CC(C)N1CC[C@@H]2[C@@H](CC1)N1CCS[Tc]13(=O)SCCN23.CC(C)N1C[C@@H]2[C@@H](C1)N1CCS[Tc]13(=O)SCCN23 RKAOIJPELGTBGE-VCCCQOPFSA-E 0.000 description 1
- PEPGERDWEWRPJT-UHFFFAOYSA-M CC1=CC=C2C=C(C3=CC=C(N(C)C)C=C3)OC2=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CCO.CN(C)C1=CC=C(C2=CC3=CC=C(Br)C=C3O2)C=C1.CN(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1.CN(C)C1=CC=C(CCl)C=C1.CN(C)C1=CC=C(COC2=CC(Br)=CC=C2C=O)C=C1.II.O=CC1=CC=C(Br)C=C1O.O[Na] Chemical compound CC1=CC=C2C=C(C3=CC=C(N(C)C)C=C3)OC2=C1.CCCC[Sn](CCCC)(CCCC)[Sn](CCCC)(CCCC)CCCC.CCO.CN(C)C1=CC=C(C2=CC3=CC=C(Br)C=C3O2)C=C1.CN(C)C1=CC=C(C2=CC3=CC=C(I)C=C3O2)C=C1.CN(C)C1=CC=C(CCl)C=C1.CN(C)C1=CC=C(COC2=CC(Br)=CC=C2C=O)C=C1.II.O=CC1=CC=C(Br)C=C1O.O[Na] PEPGERDWEWRPJT-UHFFFAOYSA-M 0.000 description 1
- WXAJBWFJOKAGEN-UHFFFAOYSA-N CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN=C(N)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CS(=O)(=O)Cl.Cl Chemical compound CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN=C(N)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CS(=O)(=O)Cl.Cl WXAJBWFJOKAGEN-UHFFFAOYSA-N 0.000 description 1
- JVFIIJOSSBNZIS-UHFFFAOYSA-N CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN=C(N)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1 Chemical compound CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=CN=C(N)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1 JVFIIJOSSBNZIS-UHFFFAOYSA-N 0.000 description 1
- UYUJDQIQDMEWCI-UHFFFAOYSA-N CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=N1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2N=C1.CC1=CN=C(N)C=N1.CC1=CN=C(N)N=C1.CC1=NN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=NN=C(N)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1 Chemical compound CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=N1.CC1=CN2C=C(C3=CC=C(N(C)C)C=C3)N=C2N=C1.CC1=CN=C(N)C=N1.CC1=CN=C(N)N=C1.CC1=NN2C=C(C3=CC=C(N(C)C)C=C3)N=C2C=C1.CC1=NN=C(N)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1.CN(C)C1=CC=C(C(=O)CBr)C=C1 UYUJDQIQDMEWCI-UHFFFAOYSA-N 0.000 description 1
- MNOKCCLURISDBW-UHFFFAOYSA-N CN(C)C.CN(C)C.CN(C)C.CN(C)C1=CC=C(C2=CN3C=C(I)C=NC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(I)N=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3N=C(I)C=CC3=N2)C=C1.IC1=CN2C=C(C3=CC=CC=C3)N=C2C=N1.IC1=CN2C=C(C3=CC=CC=C3)N=C2N=C1.IC1=NN2C=C(C3=CC=CC=C3)N=C2C=C1.NC1=NC=C(I)C=N1.NC1=NC=C(I)N=C1.NC1=NN=C(I)C=C1.[CH2+]N(C)C1=CC=C(C(=O)CBr)C=C1.[CH2+]N(C)C1=CC=C(C(=O)CBr)C=C1.[CH2+]N(C)C1=CC=C(C(=O)CBr)C=C1 Chemical compound CN(C)C.CN(C)C.CN(C)C.CN(C)C1=CC=C(C2=CN3C=C(I)C=NC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(I)N=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3N=C(I)C=CC3=N2)C=C1.IC1=CN2C=C(C3=CC=CC=C3)N=C2C=N1.IC1=CN2C=C(C3=CC=CC=C3)N=C2N=C1.IC1=NN2C=C(C3=CC=CC=C3)N=C2C=C1.NC1=NC=C(I)C=N1.NC1=NC=C(I)N=C1.NC1=NN=C(I)C=C1.[CH2+]N(C)C1=CC=C(C(=O)CBr)C=C1.[CH2+]N(C)C1=CC=C(C(=O)CBr)C=C1.[CH2+]N(C)C1=CC=C(C(=O)CBr)C=C1 MNOKCCLURISDBW-UHFFFAOYSA-N 0.000 description 1
- GQOOVXSGXOZRMJ-UHFFFAOYSA-E CN(C)C1=CC=C(C2=CN3C=C(I)C=NC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(I)N=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(N45CCS[Tc]46(=O)SCC(=O)N6CC5)C=NC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(N45CCS[Tc]46(=O)SCC(=O)N6CC5)N=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3N=C(I)C=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3N=C(N45CCS[Tc]46(=O)SCC(=O)N6CC5)C=CC3=N2)C=C1 Chemical compound CN(C)C1=CC=C(C2=CN3C=C(I)C=NC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(I)N=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(N45CCS[Tc]46(=O)SCC(=O)N6CC5)C=NC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3C=C(N45CCS[Tc]46(=O)SCC(=O)N6CC5)N=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3N=C(I)C=CC3=N2)C=C1.CN(C)C1=CC=C(C2=CN3N=C(N45CCS[Tc]46(=O)SCC(=O)N6CC5)C=CC3=N2)C=C1 GQOOVXSGXOZRMJ-UHFFFAOYSA-E 0.000 description 1
- PJNWJDYUMICJQD-UHFFFAOYSA-M CN(C)C1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CN(C)C1=CC=C(C2=NC3=C(C=C(N)C=C3)O2)C=C1.CN(C)C1=CC=C(C2=NC3=C(C=C([N+](=O)[O-])C=C3)O2)C=C1.CN(C)C1=CC=C(OC=O)C=C1.NC1=C(O)C=C([N+](=O)[O-])C=C1.[K]I Chemical compound CN(C)C1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CN(C)C1=CC=C(C2=NC3=C(C=C(N)C=C3)O2)C=C1.CN(C)C1=CC=C(C2=NC3=C(C=C([N+](=O)[O-])C=C3)O2)C=C1.CN(C)C1=CC=C(OC=O)C=C1.NC1=C(O)C=C([N+](=O)[O-])C=C1.[K]I PJNWJDYUMICJQD-UHFFFAOYSA-M 0.000 description 1
- QBSCJIFWNBFOPY-UHFFFAOYSA-M CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(N)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C([N+](=O)[O-])C=C3)O2)C=C1.CNC1=CC=C(OC=O)C=C1.NC1=C(O)C=C([N+](=O)[O-])C=C1.[K]I Chemical compound CNC1=CC=C(C2=NC3=C(C=C(I)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C(N)C=C3)O2)C=C1.CNC1=CC=C(C2=NC3=C(C=C([N+](=O)[O-])C=C3)O2)C=C1.CNC1=CC=C(OC=O)C=C1.NC1=C(O)C=C([N+](=O)[O-])C=C1.[K]I QBSCJIFWNBFOPY-UHFFFAOYSA-M 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
Definitions
- This invention relates to novel bioactive compounds, methods of diagnostic imaging using radiolabeled compounds, and methods of making radiolabeled compounds.
- AD Alzheimer's disease
- SPs senile plaques
- a ⁇ amyloid- ⁇
- NFTs neurofibrillary tangles
- Familial AD Familial AD
- APP A precursor protein
- P51 presenilin 1
- PS2 presenilin 2
- AD pathogenesis (Selkoe, D. J., “Biology of B-amyloid Precursor Protein and the Mechanism of Alzheimer's Disease,” Alzheimer's Disease, Lippincot Williams & Wilkins, Philadelphia, P.A. (1999), pp. 293-310; Selkoe, D.
- the inhibition constants (K i ) for binding to fibrillar A ⁇ aggregates of CR, CG, and 3′-bromo- and 3′-iodo derivatives of CG are 2,800, 370, 300 and 250 nM, respectively (Mathis, C. A., et al., Proc. XIIth Intl. Symp. Radiopharm. Chem., Uppsala, Sweden: 94-95 (1997)).
- Amyloidosis is a condition characterized by the accumulation of various insoluble, fibrillar proteins in the tissues of a patient.
- An amyloid deposit is formed by the aggregation of amyloid proteins, followed by the further combination of aggregates and/or amyloid proteins.
- amyloid deposits In addition to the role of amyloid deposits in Alzheimer's disease, the presence of amyloid deposits has been shown in diseases such as Mediterranean fever, Muckle-Wells syndrome, idiopathetic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down's syndrome, Scrapie, Creutzfeldt-Jacob disease, Kuru, Gerstamnn-Straussler-Scheinker syndrome, medullary carcinoma of the thyroid, Isolated atrial amyloid, ⁇ 2 -microglobulin amyloid in dialysis patients, inclusion body myositis, ⁇ 2 -amyloid deposits in muscle wasting disease, and Islets of Langerhans diabetes Type II insulinoma.
- diseases such as Mediterranean fever, Muckle-Wells syndrome, idiopathetic myeloma, amyloid polyneuropathy
- amyloid deposits in vivo are difficult, as the deposits have many of the same physical properties (e.g., density and water content) as normal tissues. Attempts to image amyloid deposits using magnetic resonance imaging (MRI) and computer-assisted tomography (CAT) have been disappointing and have detected amyloid deposits only under certain favorable conditions. In addition, efforts to label amyloid deposits with antibodies, serum amyloid P protein, or other probe molecules have provided some selectivity on the periphery of tissues, but have provided for poor imaging of tissue interiors.
- MRI magnetic resonance imaging
- CAT computer-assisted tomography
- ligands for detecting A ⁇ aggregates in the living brain must cross the intact blood-brain barrier.
- brain uptake can be improved by using ligands with relatively smaller molecular size (compared to Congo Red) and increased lipophilicity.
- Highly conjugated thioflavins S and T are commonly used as dyes for staining the A ⁇ aggregates in the AD brain (Elhaddaoui, A., et al., Biospectroscopy 1: 351-356 (1995)). These compounds are based on benzothiazole, which is relatively small in molecular size.
- thioflavins contain an ionic quarternary amine, which is permanently charged and unfavorable for brain uptake.
- the present invention provides novel compounds of Formula I, II, III or III′ that bind preferentially to amyloid aggregates.
- the present invention also provides diagnostic compositions comprising a radiolabeled compound of Formula I, II, III or III′, and a pharmaceutically acceptable carrier or diluent.
- the invention further provides a method of imaging amyloid deposits, the method comprising introducing into a patient a detectable quantity of a labeled compound of Formula I, II, III or III′ or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- the present invention also provides a method for inhibiting the aggregation of amyloid proteins, the method comprising administering to a mammal an amyloid inhibiting amount of a compound Formula I, II, III or III′ or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- a further aspect of this invention is directed to methods and intermediates useful for synthesizing the amyloid inhibiting and imaging compounds of Formula I, II, III or III′ described herein.
- FIG. 1A and FIG. 1B depict representative compounds of the present invention and the binding data for these compounds.
- a first aspect of the present invention is directed to compounds of the following Formula I:
- Ch is selected from the group consisting of:
- a rhenium radioisotope can be complexed with the Ch ligand.
- a preferred group of compounds falling within the scope of the present invention include compounds of Formula I wherein Y is selected from NR 5 , O or S.
- Especially preferred compounds of Formula I include compounds wherein Y is NR 5 or S, most preferably Y is S.
- R 5 in compounds of Formula I where Y is NR 5 are hydrogen and C 1-4 alkyl, more preferably R 5 is hydrogen or methyl, and most preferably R 5 is hydrogen.
- a preferred value of m and n in compounds of Formula I is from zero to one, more preferably zero.
- Suitable values of R 3 are Br, I, F, 125 I, 131 I, 123 I, 18 F, 76 Br, or 77 Br. Especially useful values of R 3 are 125 I, 131 I, 123 I, 18 F, 76 Br, or 77 Br, more preferably 123 I, 131 I, 76 Br or 77 Br, and most preferably 123 I. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula I wherein R 3 is Sn(alkyl) 3 .
- Preferred compounds are those of Formula I wherein R 1 and R 2 are independently one of hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, halophenyl(C 1-4 )alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR 6 in said ring, where R 6 is hydrogen or C 1-4 alkyl.
- R 1 and R 2 include, independently, hydrogen, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R 1 and R 2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR 6 in said ring, where R 6 is hydrogen or methyl.
- the present invention is also directed to compounds of Formula II:
- a preferred group of compounds include compounds of Formula II where Y is NR 4 where R 4 is hydrogen or methyl. More preferred compounds include compounds where Y is O.
- Useful values of R 3 are Br, I, F, 125 I, 131 I, 123 I, 18 F, 76 Br, or 77 Br. Especially suitable values of R 3 are 125 I, 131 I, 123 I, 18 F, 76 Br, or 77 Br, more preferably 123 I, 131 I, 76 Br or 77 Br, and most preferably 123 I. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula II wherein R 3 is Sn(alkyl) 3 .
- Preferred compounds are those of Formula II wherein R 1 and R 2 are independently one of hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, halophenyl(C 1-4 )alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR 6 in said ring, where R 6 is hydrogen or C 1-4 alkyl.
- R 1 and R 2 include, independently, hydrogen, methyl, ethyl, propyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R 1 and R 2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR 6 in said ring, where R 6 is hydrogen or methyl.
- the present invention is also directed to compounds of Formula III:
- Useful values of R 3 are Br, I, F, 125 I, 131 I, 123 I, 18 F, 76 Br, or 77 Br. Especially suitable values of R 3 are 125 I, 131 I, 123 I, 18 F, 76 Br, or 77 , more preferably 123 I, 131 I, 76 Br or 77 Br, and most preferably 123 I or 125 I. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula III wherein R 3 is Sn(alkyl) 3 .
- Preferred compounds are those of Formula III wherein R 1 and R 2 are independently one of hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, halophenyl(C 1-4 )alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR 6 in said ring, where R 6 is hydrogen or C 1-4 alkyl.
- R 1 and R 2 include, independently, hydrogen, methyl, ethyl, propyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R 1 and R 2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR 6 in said ring, where R 6 is hydrogen or methyl. Most preferably R 1 and R 2 are methyl.
- Another preferred group of compounds are compounds of Formulae I, II, or III where R 1 is —L—Ch, R 2 is hydrogen or methyl, and R 3 is I or methyl.
- a preferred Ch is Formula IV.
- a preferred L is —(CH 2 ) n — where n
- compounds of Formula III have R 1 and R 2 groups as defined above, and R 3 is —L—Ch, where L and Ch are as defined above.
- the invention is directed to compounds of Formula III′:
- R 3 Useful values of R 3 are Br, I, F, 125 I, 131 I, 123 I, 18 F, 76 Br, 77 Br or 18 F/fluoro(C 1-5 ) alkyl. Especially suitable values of R 3 are 18 F/fluoromethyl, 18 F/fluoroethyl, 18 F/fluoropropyl, 18 F/fluorobutyl, or 18 F/fluoropentyl. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula III′ wherein R 3 is Sn(alkyl) 3 .
- a and B are CH, and D is N.
- a and D are CH, and B is N.
- B and D are CH, and A is N.
- Preferred compounds are those of Formula III′ wherein R 1 and R 2 are independently one of hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, halophenyl(C 1-4 )alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR 6 in said ring, where R 6 is hydrogen or C 1-4 alkyl.
- R 1 and R 2 include, independently, hydrogen, methyl, ethyl, propyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R 1 and R 2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR 6 in said ring, where R 6 is hydrogen or methyl. Most preferably R 1 and R 2 are methyl.
- Another preferred group of compounds are compounds of Formula I, II, III or III′ where R′ is —L—Ch, R 2 is hydrogen or methyl, and R 3 is I or methyl.
- a preferred Ch is Formula IV.
- a preferred L is —(CH 2 ) n — where n is 1, 2 or 3.
- compounds of Formula III′ have R 1 and R 2 groups as defined above, and R 3 is —L—Ch, where L is a covalent bond or linking group, such as —(CH 2 ) n —, or —(CH 2 ) n —C(O)- where n is 0-5, and Ch is a tetradentate ligand capable of complexing with a metal as defined above.
- L is —(CH 2 ) n —, where n is 0, Ch is Formula XI, and R 1 and R 2 are independently hydrogen or C 1-4 alkyl. In this embodiment, it is most preferable that R 1 and R 2 are both methyl.
- the present invention is considered to include stereoisomers as well as optical isomers, e.g. mixtures of enantiomers as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in selected compounds of the present series.
- the compounds of Formula I, II, III or III′ may also be solvated, especially hydrated. Hydration may occur during manufacturing of the compounds or compositions comprising the compounds, or the hydration may occur over time due to the hygroscopic nature of the compounds.
- the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
- a first method is characterized by forming a benzothiazole of Formula I wherein Y is S by reacting a 2-aminothiophenol with either: a) a 4-aminobenzaldehyde in DMSO at a temperature in the range of 100° C.-220° C., and collecting said benzothiazole; or b) a 4-halobenzoic acid derivative in a solvent in the presence of polyphosphoric acid, collecting the product of this reaction, followed by reacting said product with an amine to form said benzothiazole, and collecting said benzothiazole; and optionally reacting a benzothiazole of Formula I wherein Y is S with (alkyl) 3 Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl benzothiazole, and collecting the product of this reaction; and optionally reacting a trialkylstanny
- a second method is characterized by forming a benzoxazole of Formula I wherein Y is O by reacting a 2-amino-5-nitrophenol with a 4-aminobenzoic acid to form a nitro-substituted benzoxazole intermediate, and collecting said intermediate; followed by catalytic hydrogenation of said nitro group to an amino group, and collecting the product of this reaction; and reacting said product with NaNO 2 in the presence of H + and potassium halide to produce a benzoxazole of Formula I wherein Y is O; and optionally reacting a benzoxazole of Formula I wherein Y is O with (alkyl) 3 Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl benzoxazole, and collecting the product of this reaction; and optionally reacting a trialkylstannyl benzoxazole of Formula I wherein Y is O with either: a) iodine in a solvent at ambient temperature,
- a third method is characterized by forming a benzimidazole of Formula I wherein Y is N by reacting a 4-bromo-1,2-diaminobenzene with either: a) a 4-aminobenzaldehyde to form a benzimidazole of Formula I wherein Y is N, and collecting the product, or b) a 4-halobenzaldehyde to form an intermediate benzimidazole, and reacting said intermediate with a monoalkylamine, dialkylamine, or heterocyclic amine in the presence of palladiumIIoxide to form a benzimidazole of Formula I wherein Y is N, and collecting the product; and optionally reacting a benzimidazole of Formula I wherein Y is N with (alkyl) 3 Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl benzimidazole, and collecting the product of this reaction; and optionally reacting
- a fourth method is characterized by forming a compound of Formula I wherein R 1 or R 2 is —L—Ch.
- the groups R 9 are both hydrogen, or can be any of the variety of protecting groups available for sulfur, including methoxymethyl, methoxyethoxymethyl, p-methoxybenzyl or benzyl. Sulfur protecting groups are described in detail in Greene, T. W. and Wuts, P. G. M., Protective Groups in Organic Synthesis, 2nd Edition, John Wiley and Sons, Inc., New York (1991).
- Protecting group R 9 can be removed by appropriate methods well known in the art of organic synthesis, such as trifluoroacetic acid, mercuric chloride or sodium in liquid ammonia. In the case of Lewis acid labile groups, including acetamidomethyl and benzamidomethyl, R 9 can be left intact. Labeling of the ligand with technetium in this case will cleave the protecting group, rendering the protected diaminedithiol equivalent to the unprotected form.
- Tc-99m complexes can be prepared as follows. A small amount of non-radiolabeled compound (1-2 mg) is dissolved in 100 ⁇ L EtOH and mixed with 200 ⁇ L HCl (1 N) and 1 mL Sn-glucoheptonate solution (containing 8-32 ⁇ g SnCl 2 and 80-320 ⁇ g Na-glucoheptonate, pH 6.67) and 50 ⁇ L EDTA solution (0.1 N). [ 99m Tc]Pertechnetate (100-200 ⁇ L; ranging from 2-20 mCi) saline solution are then added. The reaction is heated for 30 min at 100° C., then cooled to room temperature. The reaction mixture is analyzed on TLC (EtOH:conc. NH 3 9:1) for product formation and purity check. The mixture can be neutralized with phosphate buffer to pH 5.0.
- the present invention further relates to a method of preparing a technetium-99m complex according to the present invention by reacting technetium-99m in the form of a pertechnetate in the presence of a reducing agent and optionally a suitable chelator with an appropriate Ch-containing compound.
- the reducing agent serves to reduce the Tc-99m pertechnetate which is eluted from a molybdenum-technetium generator in a physiological saline solution.
- Suitable reducing agents are, for example, dithionite, formamidine sulphinic acid, diaminoethane disulphinate or suitable metallic reducing agents such as Sn(II), Fe(II), Cu(I), Ti(III) or Sb(III). Sn(II) has proven to be particularly suitable.
- technetium-99m is reacted with an appropriate compound of the invention as a salt or in the form of technetium bound to comparatively weak chelators.
- the desired technetium-99m complex is formed by ligand exchange.
- suitable chelators for the radionuclide are dicarboxylic acids, such as oxalic acid, malonic acid, succinic acid, maleic acid, orthophtalic acid, malic acid, lactic acid, tartaric acid, citric acid, ascorbic acid, salicylic acid or derivatives of these acids; phosphorus compounds such as pyrophosphates; or enolates.
- Citric acid, tartaric acid, ascorbic acid, glucoheptonic acid or a derivative thereof are particularly suitable chelators for this purpose, because a chelate of technetium-99m with one of these chelators undergoes the desired ligand exchange particularly easily.
- the most commonly used procedure for preparing [Tc ⁇ O] +3 N 2 S 2 complexes is based on stannous (II) chloride reduction of [ 99m Tc]pertechnetate, the common starting material.
- the labeling procedure normally relies on a Tc-99m ligand exchange reaction between Tc-99m (Sn)-glucoheptonate and the N 2 S 2 ligand.
- Preparation of stannous (II) chloride and preserving it in a consistent stannous (II) form is critically important for the success of the labeling reaction.
- stannous ion is in a lyophilized powder form mixed with an excess amount of glucoheptonate under an inert gas like nitrogen or argon.
- the preparation of the lyophilized stannous chloride/sodium glucoheptonate kits ensures that the labeling reaction is reproducible and predictable.
- the N 2 S 2 ligands are usually air-sensitive (thiols are easily oxidized by air) and there are subsequent reactions which lead to decomposition of the ligands.
- the most convenient and predictable method to preserve the ligands is to produce lyophilized kits containing 100-500 ⁇ g of the ligands under argon or nitrogen.
- a fifth method is characterized by forming an isoxazole of Formula II wherein Y is O by reacting a 3-halo-2-hydroxy benzaldehyde with a substituted benzamine such as 4-(halomethyl)-benzamine to form a phenoxy benzyl ether intermediate, and collecting the intermediate; followed by reacting said intermediate in a solvent in the presence of NaOMe or NaOEt to form an isoxazole of Formula II wherein Y is O, and collecting the product; and optionally reacting an isoxazole of Formula I wherein Y is O with (alkyl) 3 Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl isoxazole of Formula I wherein Y is O, and collecting the product of this reaction; and optionally reacting a trialkylstannyl isoxazole of Formula I wherein Y is O with either: a) iodine in a solvent at ambient temperature, and extracting the
- a sixth method is characterized by forming an indole of Formula II wherein Y is NR 4 by reacting a 2-nitro-4-bromo toluene with N-isopropyl-2,2′-iminodiethanol to form a N,N-dimethyl-styryl-2-nitro-4-bromo benzene intermediate, followed by reacting said intermediate with an acid chloride in the presence of triethylamine to produce an a, P-unsaturated ketone, which undergoes intramolecular annulation by heating in dioxane/water, followed by reacting with sodium hydrosulfite to form an indole of Formula II wherein Y is NR 4 , and collecting the product; and optionally reacting said indole with methyl iodide in the presence of sodium hydride to produce an indole of Formula II wherein Y is NR 4 where R 4 is methyl, and collecting the product; and optionally reacting an indole of Formula II
- a seventh method characterized by forming an imidazo [1,2a]pyridine of Formula III by reacting 2-amino-5-bromo-pyridine with either: a) a 4′-halo-1-halo-benzophenone in a solvent in the presence of sodium bicarbonate to form an intermediate imidazo[1,2a]pyridine, and collecting the product of the reaction; followed by reacting said intermediate with a monoalkylamine, dialkylamine or heterocyclic amine in the presence of palladiumIIoxide to form an imidazo[1,2a]pyridine of Formula III, or b) a 4′-amino-1-halo-acetophenone in a solvent in the presence of sodium bicarbonate to form an imidazo [1,2a]pyridine of Formula III, and collecting the product of the reaction; and optionally reacting an imidazo[1,2a]pyridine of Formula III with (alkyl) 3 Sn in a solvent in the presence of palladiumIIoxide to form a trialky
- alkyl as employed herein by itself or as part of another group refers to both straight and branched chain radicals of up to 8 carbons, preferably 6 carbons, more preferably 4 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, and isobutyl.
- alkoxy is used herein to mean a straight or branched chain alkyl radical, as defined above, unless the chain length is limited thereto, bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and the like.
- the alkoxy chain is 1 to 6 carbon atoms in length, more preferably 1-4 carbon atoms in length.
- monoalkylamine as employed herein by itself or as part of another group refers to an amino group which is substituted with one alkyl group as defined above.
- dialkylamine as employed herein by itself or as part of another group refers to an amino group which is substituted with two alkyl groups as defined above.
- halo employed herein by itself or as part of another group refers to chlorine, bromine, fluorine or iodine.
- aryl as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 12 carbons in the ring portion, preferably 6-10 carbons in the ring portion, such as phenyl, naphthyl or tetrahydronaphthyl.
- heterocycle or “heterocyclic ring”, as used herein except where noted, represents a stable 5- to 7-memebered mono-heterocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatom may optionally be oxidized.
- rings contain one nitrogen combined with one oxygen or sulfur, or two nitrogen heteroatoms.
- heterocyclic groups include piperidinyl, pyrrolyl, pyrrolidinyl, imidazolyl, imidazlinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, homopiperidinyl, homopiperazinyl, pyridazinyl, pyrazolyl, and pyrazolidinyl, most preferably thiamorpholinyl, piperazinyl, and morpholinyl.
- heteroatom is used herein to mean an oxygen atom (“O”), a sulfur atom (“S”) or a nitrogen atom (“N”). It will be recognized that when the heteroatom is nitrogen, it may form an NR a R b moiety, wherein R a and R b are, independently from one another, hydrogen or C 1-4 alkyl, C 2-4 aminoalkyl, C 1-4 halo alkyl, halo benzyl, or R 1 and R 2 are taken together to form a 5- to 7-member heterocyclic ring optionally having O, S or NR c in said ring, where R c is hydrogen or C 1-4 alkyl.
- the present invention is further directed to a methods of preparing compounds of the above Formula I, II III or III′.
- the compounds of this invention can be prepared by reactions described in Schemes 1-13.
- Schemes 1 and 2 depict a synthetic route for forming benzothiazoles of Formula I. Heating 5-bromo-2-amino-benzenethiol (Mital, R. L. and Jain, S. K., J Chem Soc (C):2148 (1969); Lin, A.-J. and Kasina, S., J Heterocycl Chem 18:759 (1981)) and 4-dimethylaminobenzaldehyde or 4-(4-methylpiperazin-1 -yl) benzaldehyde (Tanaka, A., et al., J. Med. Chem. 41:2390 (1998)) in DMSO produced benzothiazoles, 1 and 4.
- the tributyltin derivatives served two useful purposes, i) they served as intermediates for converting bromo to iodo derivatives; ii) they are also useful as starting material for preparation of radioiodinated “hot” ligand.
- Scheme 3 depicts a synthetic route in which N-monomethylated amines are prepared, and thereafter employed in the parallel synthesis of disubstituted aminophenyl benzothiazole derivatives.
- Schemes 4 through 6 depict synthetic routes for forming benzoxazoles of the present invention.
- Schemes 7, 8 and 9 depict synthetic routes for preparing indole derivatives and benzimidazole derivatives of the present invention.
- Scheme 10 depicts a synthetic route for forming benzofuran derivatives of the present invention.
- benzofurans can be prepared via an intramolecular Wittig Route (Twyman, et al., Tetrahedron Lett 40:9383 (1999)) as set forth in Scheme 11.
- Schemes 13 through 17 are directed to imidazo [1,2a] pyridine derivatives of the present invention.
- Schemes 18 and 19 depict synthetic routes for forming benzopyrimidines of the present invention.
- Scheme 20 depicts the synthesis of metal-chelated complexes of the present invention, where R 9 is as defined above, and Ar is a bicyclic system selected from the group comprising: benzothiazyl, benzoxazolyl, benzimidazolyl, benzofuranyl, imidazo[1,2a]pyridyl, and benzopyrimidyl.
- the compounds of this invention When the compounds of this invention are to be used as imaging agents, they must be labeled with suitable radioactive halogen isotopes.
- 125 I-isotopes are useful for laboratory testing, they will generally not be useful for actual diagnostic purposes because of the relatively long half-life (60 days) and low gamma-emission (30-65 Kev) of 125 I.
- the isotope 123 I has a half life of thirteen hours and gamma energy of 159 Ke V, and it is therefore expected that labeling of ligands to be used for diagnostic purposes would be with this isotope.
- Other isotopes which may be used include 131 I (half life of 2 hours).
- Suitable bromine isotopes include 77 Br and 76 Br.
- Kits for forming the imaging agents can contain, for example, a vial containing a physiologically suitable solution of an intermediate of Formula I, II, III or III′ in a concentration and at a pH suitable for optimal complexing conditions.
- the user would add to the vial an appropriate quantity of the radioisotope, e.g., Na 123 I, and an oxidant, such as hydrogen peroxide.
- the resulting labeled ligand may then be administered intravenously to a patient, and receptors in the brain imaged by means of measuring the gamma ray or photo emissions therefrom.
- the present invention also relates to a kit, comprising:
- the pertechnetate solution can be obtained by the user from a molybdenum-technetium generator. Such generators are available in a number of institutions that perform radiodiagnostic procedures. As noted above the ingredients (1) and (2) may be combined, provided they are compatible. Such a monocomponent kit, in which the combined ingredients are preferably lyophilized, is excellently suitable to be reacted by the user with the pertechnetate solution in a simple manner.
- the radioactive diagnostic agent may contain any additive such as pH controlling agents (e.g., acids, bases, buffers), stabilizers (e.g., ascorbic acid) or isotonizing agents (e.g., sodium chloride).
- pH controlling agents e.g., acids, bases, buffers
- stabilizers e.g., ascorbic acid
- isotonizing agents e.g., sodium chloride
- pharmaceutically acceptable salt refers to those carboxylate salts or acid addition salts of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- salts refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention.
- salts derived from non-toxic organic acids such as aliphatic mono and dicarboxylic acids, for example acetic acid, phenyl-substituted alkanoic acids, hydroxy alkanoic and alkanedioic acids, aromatic acids, and aliphatic and aromatic sulfonic acids.
- aliphatic mono and dicarboxylic acids for example acetic acid, phenyl-substituted alkanoic acids, hydroxy alkanoic and alkanedioic acids, aromatic acids, and aliphatic and aromatic sulfonic acids.
- These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
- Further representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactiobionate and laurylsulphonate salts, propionate, pivalate, cyclamate, isethionate, and the like.
- alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like
- nontoxic ammonium, quaternary ammonium and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
- ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like See, for example, Berge S. M, et al., Pharmaceutical Salts, J. Pharm. Sci. 66:1-19 (1977) which is incorporated herein by reference.
- a labeled compound of Formula I, II, III or III′ is introduced into a tissue or a patient in a detectable quantity.
- the compound is typically part of a pharmaceutical composition and is administered to the tissue or the patient by methods well known to those skilled in the art.
- the compound can be administered either orally, rectally, parenterally (intravenous, by intramuscularly or subcutaneously), intracistemally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments or drops), or as a buccal or nasal spray.
- the labeled compound is introduced into a patient in a detectable quantity and after sufficient time has passed for the compound to become associated with amyloid deposits, the labeled compound is detected noninvasively inside the patient.
- a labeled compound of Formula I, II, III or III′ is introduced into a patient, sufficient time is allowed for the compound to become associated with amyloid deposits, and then a sample of tissue from the patient is removed and the labeled compound in the tissue is detected apart from the patient.
- a tissue sample is removed from a patient and a labeled compound of Formula I, II, III or III′ is introduced into the tissue sample. After a sufficient amount of time for the compound to become bound to amyloid deposits, the compound is detected.
- the administration of the labeled compound to a patient can be by a general or local administration route.
- the labeled compound may be administered to the patient such that it is delivered throughout the body.
- the labeled compound can be administered to a specific organ or tissue of interest. For example, it is desirable to locate and quantitate amyloid deposits in the brain in order to diagnose or track the progress of Alzheimer's disease in a patient.
- tissue means a part of a patient's body. Examples of tissues include the brain, heart, liver, blood vessels, and arteries.
- a detectable quantity is a quantity of labeled compound necessary to be detected by the detection method chosen. The amount of a labeled compound to be introduced into a patient in order to provide for detection can readily be determined by those skilled in the art. For example, increasing amounts of the labeled compound can be given to a patient until the compound is detected by the detection method of choice. A label is introduced into the compounds to provide for detection of the compounds.
- patient means humans and other animals. Those skilled in the art are also familiar with determining the amount of time sufficient for a compound to become associated with amyloid deposits. The amount of time necessary can easily be determined by introducing a detectable amount of a labeled compound of Formulae I-III′ into a patient and then detecting the labeled compound at various times after administration.
- association means a chemical interaction between the labeled compound and the amyloid deposit. Examples of associations include covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-hydrophobic interactions, and complexes.
- MRI magnetic resonance imaging
- PET positron emission tomography
- SPECT single photon emission computed tomography
- the label that is introduced into the compound will depend on the detection method desired. For example, if PET is selected as a detection method, the compound must possess a positron-emitting atom, such as 11 C or 18 F.
- the radioactive diagnostic agent should have sufficient radioactivity and radioactivity concentration which can assure reliable diagnosis.
- the radioactive metal being technetium-99m, it may be included usually in an amount of 0.1 to 50 mCi in about 0.5 to 5.0 ml at the time of administration.
- the amount of a compound of Formulae I-III′ may be such as sufficient to form a stable chelate compound with the radioactive metal.
- the radioactive diagnostic agent may contain any additive such as pH controlling agents (e.g., acids, bases, buffers), stabilizers (e.g., ascorbic acid) or isotonizing agents (e.g., sodium chloride).
- pH controlling agents e.g., acids, bases, buffers
- stabilizers e.g., ascorbic acid
- isotonizing agents e.g., sodium chloride
- the imaging of amyloid deposits can also be carried out quantitatively so that the amount of amyloid deposits can be determined.
- Preferred compounds for imaging include a radioisotope such as 123 I, 125 I, 131 I, 18 F, 76 Br or 77 Br.
- the present invention is also directed at a method of imaging amyloid deposits.
- One of the key prerequisites for an in vivo imaging agent of the brain is the ability to cross the intact blood-brain barrier after a bolus iv injection.
- the compounds of this invention possess a core ring system comprised of various substituted, fused 5- and 6-member aromatic rings.
- Another aspect of the invention is a method of inhibiting amyloid plaque aggregation.
- the present invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, by administering to a patient an amyloid inhibiting amount of a compound of the above Formula I, II, III or III′.
- an amyloid inhibiting amount by simply administering a compound of Formula I, II, III or III′ to a patient in increasing amounts until the growth of amyloid deposits is decreased or stopped.
- the rate of growth can be assessed using imaging as described above or by taking a tissue sample from a patient and observing the amyloid deposits therein.
- the compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is sufficient.
- the specific dosage used can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
- the compound, [ 125 I] 18 was prepared using iododestannylation reactions with tributyltin precursor 17. Hydrogen peroxide (50 ⁇ L, 3% w/v) was added to a mixture of 50 ⁇ L of the correspondent tributyltin precursor (1 ⁇ g/ ⁇ L EtOH), 50 ⁇ L of 1N HCl and [ 125/123 I]NaI (1-5 mCi) in a sealed vial. The reaction was allowed to proceed for 10 min at room temperature and terminated by addition of 100 ⁇ L of sat. NaHSO 3 .
- the reaction mixture was either directly extracted (styrylbenzenes) with ethylacetate (3 ⁇ 1 mL) or extracted after neutralization with saturated sodium bicarbonate solution (thioflavins). The combined extracts were evaporated to dryness.
- styrylbenzenes the residues were dissolved in 100 ⁇ L of EtOH and purified by HPLC using a reverse phase column (Waters ubondpad, 3.9 ⁇ 300 mm) with an isocratic solvent of 65% acetonitrile-35% trifluoroacetic acid (0.1%) in a flow rate of 0.8 mL/min.
- Thioflavins were purified on a C4 column (Phenomenex Inc, Torrance, Calif.) eluted with an isocratic solvent of 80% acetonitrile-20% 3,3-dimethyl-glutaric acid (5 mM, pH 7.0) in a flow rate of 0.8 mL/min.
- the desired fractions containing the product were collected, condensed and re-extracted with ethylacetate.
- the no-carrier-added products were evaporated to dryness and re-dissolved in 100% EtOH (1 ⁇ Ci/ ⁇ L),
- the final 125 I 18, with a specific activity of 2,200 Ci/mmole and a greater than 95% radiochemical purity were stored at ⁇ 20° C. up to 6 weeks for in vitro binding and autoradiography studies.
- Partition coefficients were measured by mixing the [ 125 I] tracer with 3 g each of 1-octanol and buffer (0.1 M phosphate, pH 7.4) in a test tube. The test tube was vortexed for 3 min at room temperature, followed by centrifugation for 5 min. Two weighed samples (0.5 g each) from the 1-octanol and buffer layers were counted in a well counter. The partition coefficient was determined by calculating the ratio of cpm/g of 1-octanol to that of buffer. Samples from the 1-octanol layer were re-partitioned until consistent partitions of coefficient values were obtained. The measurement was done in triplicate and repeated three times.
- the solid forms of peptides A ⁇ (1-40) and A ⁇ (1-42) were purchased from Bachem (King of Prussia, P.A.). Aggregation of peptides were carried out by gently dissolving the peptide [0.5 mg/mL for A ⁇ (I-40) and 0.25 mg/mL for A ⁇ (1-42) in a buffer solution (pH 7.4) containing 10 mM sodium phosphate and 1 mM EDTA. The solutions were incubated at 37° C. for 36-42 h with gentle and constant shaking. Binding studies were carried out in 12 ⁇ 75 mm borosilicate glass tubes according to the procedure described with some modifications (Klunk, W. E., et al., Biol.
Abstract
This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Description
This application claims the benefit of U.S. Provisional Application No. 60/285,282, filed Apr. 23,2001, the contents of which are entirely incorporated by reference herein.
Part of the work performed during development of this invention utilized U.S. Government funds. The U.S. Government has certain rights in this invention under grant numbers NS-18509 and PO1 AG-11542 awarded by the Institute for the Study of Aging.
1. Field of the Invention
This invention relates to novel bioactive compounds, methods of diagnostic imaging using radiolabeled compounds, and methods of making radiolabeled compounds.
2. Background Art
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, irreversible memory loss, disorientation, and language impairment. Postmortem examination of AD brain sections reveals abundant senile plaques (SPs) composed of amyloid-β (Aβ) peptides and numerous neurofibrillary tangles (NFTs) formed by filaments of highly phosphorylated tau proteins (for recent reviews and additional citations see Ginsberg, S. D., et al., “Molecular Pathology of Alzheimer's Disease and Related Disorders,” in Cerebral Cortex. Neurodegenerative and Age-related Changes in Structure and Function of Cerebral Cortex, Kluwer Academic/Plenum, New York (1999), pp. 603-654; Vogelsberg-Ragaglia, V., et al, “Cell Biology of Tau and Cytoskeletal Pathology in Alzheimer's Disease,” Alzheimer's Disease, Lippincot, Williams & Wilkins, Philadelphia, P.A. (1999), pp.359-372). Familial AD (FAD) is caused by multiple mutations in the A precursor protein (APP), presenilin 1 (P51) and presenilin 2 (PS2) genes (Ginsberg, S. D., et al., “Molecular Pathology of Alzheimer's Disease and Related Disorders,” in Cerebral Cortex: Neurodegenerative and Age-related Changes in Structure and Function of Cerebral Cortex, Kluwer Academic/Plenum, New York (1999), pp. 603-654; Vogelsberg-Ragaglia, V., et al., “Cell Biology of Tau and Cytoskeletal Pathology in Alzheimer's Disease,” Alzheimer's Disease, Lippincot, Williams & Wilkins, Philadelphia, P.A. (1999), pp. 359-372).
While the exact mechanisms underlying AD are not fully understood, all pathogenic FAD mutations studied thus far increase production of the more amyloidogenic 42-43 amino-acid long form of the Aβ peptide. Thus, at least in FAD, dysregulation of Aβ production appears to be sufficient to induce a cascade of events leading to neurodegeneration. Indeed, the amyloid cascade hypothesis suggests that formation of extracellular fibrillar Aβ aggregates in the brain may be a pivotal event in AD pathogenesis (Selkoe, D. J., “Biology of B-amyloid Precursor Protein and the Mechanism of Alzheimer's Disease,” Alzheimer's Disease, Lippincot Williams & Wilkins, Philadelphia, P.A. (1999), pp. 293-310; Selkoe, D. J., J. Am. Med. Assoc. 283:1615-1617 (2000); Naslund, J., et al., J. Am. Med. Assoc. 283:1571-1577 (2000); Golde, T. E., et al., Biochimica et Biophysica Acta 1502:172-187 (2000)).
Various approaches in trying to inhibit the production and reduce the accumulation of fibrillar Aβ in the brain are currently being evaluated as potential therapies for AD (Skovronsky, D. M. and Lee, V. M., Trends Pharmacol. Sci. 21:161-163 (2000); Vassar, R., et al., Science 286:735-741 (1999); Wolfe, M. S., et al., J. Med. Chem. 41:6-9 (1998); Moore, C. L., et al., J. Med. Chem. 43:3434-3442 (2000); Findeis, M. A., Biochimica et Biophysica Acta 1502:76-84 (2000); Kuner, P., Bohrmann, et al., J. Biol. Chem. 275:1673-1678 (2000)). It is therefore of great interest to develop ligands that specifically bind fibrillar Aβ aggregates. Since extracellular SPs are accessible targets, these new ligands could be used as in vivo diagnostic tools and as probes to visualize the progressive deposition of Aβ in studies of AD amyloidogenesis in living patients.
To this end, several interesting approaches for developing fibrillar Aβ aggregate-specific ligands have been reported (Ashburn, T. T., et al., Chem. Biol. 3:351-358 (1996); Han, G., et al., J. Am. Chem. Soc. 118:4506-4507 (1996); Klunk, W. E., et al., Biol. Psychiatry 35:627 (1994); Klunk, W. E., et al., Neurobiol. Aging 16:541-548 (1995); Klunk, W. E., et al., Society for Neuroscience Abstract 23:1638 (1997); Mathis, C. A., et al., Proc. XIIth Intl. Symp. Radiopharm. Chem., Uppsala, Sweden: 94-95 (1997); Lorenzo, A. and Yankner, B. A., Proc. Natl. Acad. Sci. US.A. 91:12243-12247 (1994); Zhen, W., et al., J. Med. Chem. 42:2805-2815 (1999)). The most attractive approach is based on highly conjugated chrysamine-G (CG) and Congo red (CR), and the latter has been used for fluorescent staining of SPs and NFTs in postmortem AD brain sections (Ashburn, T. T., et al., Chem. Biol. 3:351-358 (1996); Klunk, W. E., et al., J. Histochem. Cytochem. 37:1273-1281 (1989)). The inhibition constants (Ki) for binding to fibrillar Aβ aggregates of CR, CG, and 3′-bromo- and 3′-iodo derivatives of CG are 2,800, 370, 300 and 250 nM, respectively (Mathis, C. A., et al., Proc. XIIth Intl. Symp. Radiopharm. Chem., Uppsala, Sweden: 94-95 (1997)). These compounds have been shown to bind selectively to Aβ (1-40) peptide aggregates in vitro as well as to fibrillar Aβ deposits in AD brain sections (Mathis, C. A., et al., Proc. XIIth Intl. Symp. Radiopharm. Chem., Uppsala, Sweden: 94-95 (1997)).
Amyloidosis is a condition characterized by the accumulation of various insoluble, fibrillar proteins in the tissues of a patient. An amyloid deposit is formed by the aggregation of amyloid proteins, followed by the further combination of aggregates and/or amyloid proteins.
In addition to the role of amyloid deposits in Alzheimer's disease, the presence of amyloid deposits has been shown in diseases such as Mediterranean fever, Muckle-Wells syndrome, idiopathetic myeloma, amyloid polyneuropathy, amyloid cardiomyopathy, systemic senile amyloidosis, amyloid polyneuropathy, hereditary cerebral hemorrhage with amyloidosis, Down's syndrome, Scrapie, Creutzfeldt-Jacob disease, Kuru, Gerstamnn-Straussler-Scheinker syndrome, medullary carcinoma of the thyroid, Isolated atrial amyloid, β2-microglobulin amyloid in dialysis patients, inclusion body myositis, β2-amyloid deposits in muscle wasting disease, and Islets of Langerhans diabetes Type II insulinoma.
Thus, a simple, noninvasive method for detecting and quantitating amyloid deposits in a patient has been eagerly sought. Presently, detection of amyloid deposits involves histological analysis of biopsy or autopsy materials. Both methods have drawbacks. For example, an autopsy can only be used for a postmortem diagnosis.
The direct imaging of amyloid deposits in vivo is difficult, as the deposits have many of the same physical properties (e.g., density and water content) as normal tissues. Attempts to image amyloid deposits using magnetic resonance imaging (MRI) and computer-assisted tomography (CAT) have been disappointing and have detected amyloid deposits only under certain favorable conditions. In addition, efforts to label amyloid deposits with antibodies, serum amyloid P protein, or other probe molecules have provided some selectivity on the periphery of tissues, but have provided for poor imaging of tissue interiors.
Potential ligands for detecting Aβ aggregates in the living brain must cross the intact blood-brain barrier. Thus brain uptake can be improved by using ligands with relatively smaller molecular size (compared to Congo Red) and increased lipophilicity. Highly conjugated thioflavins (S and T) are commonly used as dyes for staining the Aβ aggregates in the AD brain (Elhaddaoui, A., et al., Biospectroscopy 1: 351-356 (1995)). These compounds are based on benzothiazole, which is relatively small in molecular size. However, thioflavins contain an ionic quarternary amine, which is permanently charged and unfavorable for brain uptake.
Thus, it would be useful to have a noninvasive technique for imaging and quantitating amyloid deposits in a patient. In addition, it would be useful to have compounds that inhibit the aggregation of amyloid proteins to form amyloid deposits and a method for determining a compound's ability to inhibit amyloid protein aggregation.
BRIEF SUMMARY OF THE INVENTION
The present invention provides novel compounds of Formula I, II, III or III′ that bind preferentially to amyloid aggregates.
The present invention also provides diagnostic compositions comprising a radiolabeled compound of Formula I, II, III or III′, and a pharmaceutically acceptable carrier or diluent.
The invention further provides a method of imaging amyloid deposits, the method comprising introducing into a patient a detectable quantity of a labeled compound of Formula I, II, III or III′ or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
The present invention also provides a method for inhibiting the aggregation of amyloid proteins, the method comprising administering to a mammal an amyloid inhibiting amount of a compound Formula I, II, III or III′ or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
A further aspect of this invention is directed to methods and intermediates useful for synthesizing the amyloid inhibiting and imaging compounds of Formula I, II, III or III′ described herein.
A first aspect of the present invention is directed to compounds of the following Formula I:
-
- Y is CH, NR5, O, S or CH═N, where R5 is hydrogen or a C1-4 alkyl;
- m and n are both zero, or m and n are both 1;
- R3 is CH3, Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br or Sn(alkyl)3;
- R1 and R2 are independently hydrogen, C1-4 alkyl, CC2-4 aminoalkyl, C1-4 haloalkyl, haloarylalkyl, —L—Ch, or R′ and R2 are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S or NR6 in said ring, where R6 is hydrogen or C1-4 alkyl; and
- R4 is C1-4 alkyl; and
- L is a covalent bond or a linking group, such as —(CH2)n— or —(CH2)n—C(O)— where n is 1-5; and
- Ch is a tetradentate ligand capable of complexing with a metal, such as a ligand selected from the group consisting of:
-
-
-
- where R9 is hydrogen or a sulfur protecting group, such as methoxymethyl, methoxyethoxymethyl, p-methoxybenzyl or benzyl, and the other variable groups have the preferred values mentioned herein.
-
-
In this embodiment, compounds having Ch ligands, such as those of Formulae VIII, IX, X and XI are complexed with 99m-pertechnetate, as described herein to form metal chelates where Ch is selected from the group consisting of:
Additionally, a rhenium radioisotope can be complexed with the Ch ligand.
A preferred group of compounds falling within the scope of the present invention include compounds of Formula I wherein Y is selected from NR5, O or S. Especially preferred compounds of Formula I include compounds wherein Y is NR5 or S, most preferably Y is S.
Preferred values of R5 in compounds of Formula I where Y is NR5 are hydrogen and C1-4 alkyl, more preferably R5 is hydrogen or methyl, and most preferably R5 is hydrogen.
A preferred value of m and n in compounds of Formula I is from zero to one, more preferably zero.
Suitable values of R3 are Br, I, F, 125I, 131I, 123I, 18F, 76Br, or 77Br. Especially useful values of R3 are 125I, 131I, 123I, 18F, 76Br, or 77Br, more preferably 123I, 131I, 76Br or 77Br, and most preferably 123I. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula I wherein R3 is Sn(alkyl)3.
Preferred compounds are those of Formula I wherein R1 and R2 are independently one of hydrogen, C1-4 alkyl, C1-4 haloalkyl, halophenyl(C1-4)alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR6 in said ring, where R6 is hydrogen or C1-4 alkyl. Useful values of R1 and R2 include, independently, hydrogen, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R1 and R2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR6 in said ring, where R6 is hydrogen or methyl.
The present invention is also directed to compounds of Formula II:
-
- Y is O or NR4 where R4 is hydrogen or C1-4 alkyl;
- R3 is Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br or Sn(alkyl)3;
- R1 and R2 are independently hydrogen, C1-4 alkyl, C2-4 aminoalkyl, C1-4 haloalkyl, haloarylalkyl, or R1 and R2 are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S or NR5 in said ring, where
- R5 is hydrogen or C1-4 alkyl.
A preferred group of compounds include compounds of Formula II where Y is NR4 where R4 is hydrogen or methyl. More preferred compounds include compounds where Y is O.
Useful values of R3 are Br, I, F, 125I, 131I, 123I, 18F, 76Br, or 77Br. Especially suitable values of R3 are 125I, 131I, 123I, 18F, 76Br, or 77Br, more preferably 123I, 131I, 76Br or 77Br, and most preferably 123I. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula II wherein R3 is Sn(alkyl)3.
Preferred compounds are those of Formula II wherein R1 and R2 are independently one of hydrogen, C1-4 alkyl, C1-4 haloalkyl, halophenyl(C1-4)alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR6 in said ring, where R6 is hydrogen or C1-4 alkyl. Useful values of R1 and R2 include, independently, hydrogen, methyl, ethyl, propyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R1 and R2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR6 in said ring, where R6 is hydrogen or methyl. The present invention is also directed to compounds of Formula III:
-
- R3 is Br, I, F, 125I, 131I, 123I, 18F, 76Br or Sn(alkyl)3;
- R1 and R2 are independently hydrogen, C1-4 alkyl, C2-4 aminoalkyl, C1-4 haloalkyl, haloarylalkyl, —L—Ch, or R1 and R2 are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S or NR5 in said ring, where R5 is hydrogen or C1-4 alkyl.
Useful values of R3 are Br, I, F, 125I, 131I, 123I, 18F, 76Br, or 77Br. Especially suitable values of R3 are 125I, 131I, 123I, 18F, 76Br, or 77, more preferably 123I, 131I, 76Br or 77Br, and most preferably 123I or 125I. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula III wherein R3 is Sn(alkyl)3.
Preferred compounds are those of Formula III wherein R1 and R2 are independently one of hydrogen, C1-4 alkyl, C1-4 haloalkyl, halophenyl(C1-4)alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR6 in said ring, where R6 is hydrogen or C1-4 alkyl. Useful values of R1 and R2 include, independently, hydrogen, methyl, ethyl, propyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R1 and R2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR6 in said ring, where R6 is hydrogen or methyl. Most preferably R1 and R2 are methyl.
Another preferred group of compounds are compounds of Formulae I, II, or III where R1 is —L—Ch, R2 is hydrogen or methyl, and R3 is I or methyl. A preferred Ch is Formula IV. A preferred L is —(CH2)n— where n
is 1, 2 or 3.
In a separate embodiment, compounds of Formula III have R1 and R2 groups as defined above, and R3 is —L—Ch, where L and Ch are as defined above.
In another embodiment, the invention is directed to compounds of Formula III′:
-
- A, B and D and CH or N,
- provided that no more than two of A, B and D is N;
- R3 is Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br, haloalkyl or Sn(alkyl)3;
- R1 and R2 are independently hydrogen, C1-4 alkyl, C2-4 aminoalkyl, C1-4 haloalkyl, haloarylalkyl, —L—Ch, or R1 and R2 are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S or NR5 in said ring, where R5 is hydrogen or C1-4 alkyl.
Useful values of R3 are Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br or 18F/fluoro(C1-5) alkyl. Especially suitable values of R3 are 18F/fluoromethyl, 18F/fluoroethyl, 18F/fluoropropyl, 18F/fluorobutyl, or 18F/fluoropentyl. Preferred embodiments also include intermediates useful in the preparation of compounds of Formula III′ wherein R3 is Sn(alkyl)3.
In a preferred group of compounds, A and B are CH, and D is N. In another preferred group of compounds, A and D are CH, and B is N. In another preferred group of compounds, B and D are CH, and A is N.
Preferred compounds are those of Formula III′ wherein R1 and R2 are independently one of hydrogen, C1-4 alkyl, C1-4 haloalkyl, halophenyl(C1-4)alkyl, or are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O or NR6 in said ring, where R6 is hydrogen or C1-4 alkyl. Useful values of R1 and R2 include, independently, hydrogen, methyl, ethyl, propyl, butyl, t-butyl, isobutyl, 3-fluoropropyl, 4-fluorobutyl, or 4-fluorobenzyl, or R1 and R2 are taken together with the nitrogen to which they are attached to form a piperidinyl ring having NR6 in said ring, where R6 is hydrogen or methyl. Most preferably R1 and R2 are methyl. Another preferred group of compounds are compounds of Formula I, II, III or III′ where R′ is —L—Ch, R2 is hydrogen or methyl, and R3 is I or methyl. A preferred Ch is Formula IV. A preferred L is —(CH2)n— where n is 1, 2 or 3.
In a separate embodiment, compounds of Formula III′ have R1 and R2 groups as defined above, and R3 is —L—Ch, where L is a covalent bond or linking group, such as —(CH2)n—, or —(CH2)n—C(O)- where n is 0-5, and Ch is a tetradentate ligand capable of complexing with a metal as defined above. Most preferably, L is —(CH2)n—, where n is 0, Ch is Formula XI, and R1 and R2 are independently hydrogen or C1-4 alkyl. In this embodiment, it is most preferable that R1 and R2 are both methyl.
It is also to be understood that the present invention is considered to include stereoisomers as well as optical isomers, e.g. mixtures of enantiomers as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in selected compounds of the present series.
The compounds of Formula I, II, III or III′ may also be solvated, especially hydrated. Hydration may occur during manufacturing of the compounds or compositions comprising the compounds, or the hydration may occur over time due to the hygroscopic nature of the compounds. In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
When any variable occurs more than one time in any constituent or in Formula I, II, III or III′, its definition on each occurrence is independent of its definition at every other occurrence. Also combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
Another aspect of this invention is related to methods of preparing compounds of Formula I, II, III or III′. A first method is characterized by forming a benzothiazole of Formula I wherein Y is S by reacting a 2-aminothiophenol with either: a) a 4-aminobenzaldehyde in DMSO at a temperature in the range of 100° C.-220° C., and collecting said benzothiazole; or b) a 4-halobenzoic acid derivative in a solvent in the presence of polyphosphoric acid, collecting the product of this reaction, followed by reacting said product with an amine to form said benzothiazole, and collecting said benzothiazole; and optionally reacting a benzothiazole of Formula I wherein Y is S with (alkyl)3Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl benzothiazole, and collecting the product of this reaction; and optionally reacting a trialkylstannyl benzothiazole of Formula I wherein Y is S with either: a) iodine in a solvent at ambient temperature, and extracting the product; or b) NaI or Na[125I]I in the presence of hydrogen peroxide, and extracting the product.
A second method is characterized by forming a benzoxazole of Formula I wherein Y is O by reacting a 2-amino-5-nitrophenol with a 4-aminobenzoic acid to form a nitro-substituted benzoxazole intermediate, and collecting said intermediate; followed by catalytic hydrogenation of said nitro group to an amino group, and collecting the product of this reaction; and reacting said product with NaNO2 in the presence of H+ and potassium halide to produce a benzoxazole of Formula I wherein Y is O; and optionally reacting a benzoxazole of Formula I wherein Y is O with (alkyl)3Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl benzoxazole, and collecting the product of this reaction; and optionally reacting a trialkylstannyl benzoxazole of Formula I wherein Y is O with either: a) iodine in a solvent at ambient temperature, and extracting the product; or b) NaI or Na[125I]I in the presence of hydrogen peroxide, and extracting the product.
A third method is characterized by forming a benzimidazole of Formula I wherein Y is N by reacting a 4-bromo-1,2-diaminobenzene with either: a) a 4-aminobenzaldehyde to form a benzimidazole of Formula I wherein Y is N, and collecting the product, or b) a 4-halobenzaldehyde to form an intermediate benzimidazole, and reacting said intermediate with a monoalkylamine, dialkylamine, or heterocyclic amine in the presence of palladiumIIoxide to form a benzimidazole of Formula I wherein Y is N, and collecting the product; and optionally reacting a benzimidazole of Formula I wherein Y is N with (alkyl)3Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl benzimidazole, and collecting the product of this reaction; and optionally reacting a trialkylstannyl benzimidazole of Formula I wherein Y is N with either: a) iodine in a solvent at ambient temperature, and extracting the product; or b) NaI or Na[125I]I in the presence of hydrogen peroxide, and extracting the product.
A fourth method is characterized by forming a compound of Formula I wherein R1 or R2 is —L—Ch. In embodiments where R1 or R2 is —L—Ch, the groups R9 are both hydrogen, or can be any of the variety of protecting groups available for sulfur, including methoxymethyl, methoxyethoxymethyl, p-methoxybenzyl or benzyl. Sulfur protecting groups are described in detail in Greene, T. W. and Wuts, P. G. M., Protective Groups in Organic Synthesis, 2nd Edition, John Wiley and Sons, Inc., New York (1991). Protecting group R9 can be removed by appropriate methods well known in the art of organic synthesis, such as trifluoroacetic acid, mercuric chloride or sodium in liquid ammonia. In the case of Lewis acid labile groups, including acetamidomethyl and benzamidomethyl, R9 can be left intact. Labeling of the ligand with technetium in this case will cleave the protecting group, rendering the protected diaminedithiol equivalent to the unprotected form.
Tc-99m complexes can be prepared as follows. A small amount of non-radiolabeled compound (1-2 mg) is dissolved in 100 μL EtOH and mixed with 200 μL HCl (1 N) and 1 mL Sn-glucoheptonate solution (containing 8-32 μg SnCl2 and 80-320 μg Na-glucoheptonate, pH 6.67) and 50 μL EDTA solution (0.1 N). [99mTc]Pertechnetate (100-200 μL; ranging from 2-20 mCi) saline solution are then added. The reaction is heated for 30 min at 100° C., then cooled to room temperature. The reaction mixture is analyzed on TLC (EtOH:conc. NH3 9:1) for product formation and purity check. The mixture can be neutralized with phosphate buffer to pH 5.0.
The present invention further relates to a method of preparing a technetium-99m complex according to the present invention by reacting technetium-99m in the form of a pertechnetate in the presence of a reducing agent and optionally a suitable chelator with an appropriate Ch-containing compound.
The reducing agent serves to reduce the Tc-99m pertechnetate which is eluted from a molybdenum-technetium generator in a physiological saline solution. Suitable reducing agents are, for example, dithionite, formamidine sulphinic acid, diaminoethane disulphinate or suitable metallic reducing agents such as Sn(II), Fe(II), Cu(I), Ti(III) or Sb(III). Sn(II) has proven to be particularly suitable.
For the above-mentioned complex-forming reaction, technetium-99m is reacted with an appropriate compound of the invention as a salt or in the form of technetium bound to comparatively weak chelators. In the latter case the desired technetium-99m complex is formed by ligand exchange. Examples of suitable chelators for the radionuclide are dicarboxylic acids, such as oxalic acid, malonic acid, succinic acid, maleic acid, orthophtalic acid, malic acid, lactic acid, tartaric acid, citric acid, ascorbic acid, salicylic acid or derivatives of these acids; phosphorus compounds such as pyrophosphates; or enolates. Citric acid, tartaric acid, ascorbic acid, glucoheptonic acid or a derivative thereof are particularly suitable chelators for this purpose, because a chelate of technetium-99m with one of these chelators undergoes the desired ligand exchange particularly easily.
The most commonly used procedure for preparing [TcνO]+3N2S2 complexes is based on stannous (II) chloride reduction of [99mTc]pertechnetate, the common starting material. The labeling procedure normally relies on a Tc-99m ligand exchange reaction between Tc-99m (Sn)-glucoheptonate and the N2S2 ligand. Preparation of stannous (II) chloride and preserving it in a consistent stannous (II) form is critically important for the success of the labeling reaction. To stabilize the air-sensitive stannous ion it is a common practice in nuclear medicine to use a lyophilized kit, in which the stannous ion is in a lyophilized powder form mixed with an excess amount of glucoheptonate under an inert gas like nitrogen or argon. The preparation of the lyophilized stannous chloride/sodium glucoheptonate kits ensures that the labeling reaction is reproducible and predictable. The N2S2 ligands are usually air-sensitive (thiols are easily oxidized by air) and there are subsequent reactions which lead to decomposition of the ligands. The most convenient and predictable method to preserve the ligands is to produce lyophilized kits containing 100-500 μg of the ligands under argon or nitrogen.
A fifth method is characterized by forming an isoxazole of Formula II wherein Y is O by reacting a 3-halo-2-hydroxy benzaldehyde with a substituted benzamine such as 4-(halomethyl)-benzamine to form a phenoxy benzyl ether intermediate, and collecting the intermediate; followed by reacting said intermediate in a solvent in the presence of NaOMe or NaOEt to form an isoxazole of Formula II wherein Y is O, and collecting the product; and optionally reacting an isoxazole of Formula I wherein Y is O with (alkyl)3Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl isoxazole of Formula I wherein Y is O, and collecting the product of this reaction; and optionally reacting a trialkylstannyl isoxazole of Formula I wherein Y is O with either: a) iodine in a solvent at ambient temperature, and extracting the product; or b) NaI or Na[125I]I in the presence of hydrogen peroxide, and extracting the product.
A sixth method is characterized by forming an indole of Formula II wherein Y is NR4 by reacting a 2-nitro-4-bromo toluene with N-isopropyl-2,2′-iminodiethanol to form a N,N-dimethyl-styryl-2-nitro-4-bromo benzene intermediate, followed by reacting said intermediate with an acid chloride in the presence of triethylamine to produce an a, P-unsaturated ketone, which undergoes intramolecular annulation by heating in dioxane/water, followed by reacting with sodium hydrosulfite to form an indole of Formula II wherein Y is NR4, and collecting the product; and optionally reacting said indole with methyl iodide in the presence of sodium hydride to produce an indole of Formula II wherein Y is NR4 where R4 is methyl, and collecting the product; and optionally reacting an indole of Formula II wherein Y is NR4 with (alkyl)3Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl indole of Formula II wherein Y is NR4, and collecting the product of this reaction; and optionally reacting a trialkylstannyl indole of Formula II wherein Y is NR4 with either: a) iodine in a solvent at ambient temperature, and extracting the product; or b) NaI or Na[125I]I in the presence of hydrogen peroxide, and extracting the product.
A seventh method characterized by forming an imidazo [1,2a]pyridine of Formula III by reacting 2-amino-5-bromo-pyridine with either: a) a 4′-halo-1-halo-benzophenone in a solvent in the presence of sodium bicarbonate to form an intermediate imidazo[1,2a]pyridine, and collecting the product of the reaction; followed by reacting said intermediate with a monoalkylamine, dialkylamine or heterocyclic amine in the presence of palladiumIIoxide to form an imidazo[1,2a]pyridine of Formula III, or b) a 4′-amino-1-halo-acetophenone in a solvent in the presence of sodium bicarbonate to form an imidazo [1,2a]pyridine of Formula III, and collecting the product of the reaction; and optionally reacting an imidazo[1,2a]pyridine of Formula III with (alkyl)3Sn in a solvent in the presence of palladiumIIoxide to form a trialkylstannyl imidazo[1,2a]pyridine of Formula III, and collecting the product of this reaction; and optionally reacting a trialkylstannyl imidazo[1,2a]pyridine of Formula III with either: a) iodine in a solvent at ambient temperature, and extracting the product; or b) NaI or Na[1251]I in the presence of hydrogen peroxide, and extracting the product.
The term “alkyl” as employed herein by itself or as part of another group refers to both straight and branched chain radicals of up to 8 carbons, preferably 6 carbons, more preferably 4 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, and isobutyl.
The term “alkoxy” is used herein to mean a straight or branched chain alkyl radical, as defined above, unless the chain length is limited thereto, bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, and the like. Preferably the alkoxy chain is 1 to 6 carbon atoms in length, more preferably 1-4 carbon atoms in length.
The term “monoalkylamine” as employed herein by itself or as part of another group refers to an amino group which is substituted with one alkyl group as defined above.
The term “dialkylamine” as employed herein by itself or as part of another group refers to an amino group which is substituted with two alkyl groups as defined above.
The term “halo” employed herein by itself or as part of another group refers to chlorine, bromine, fluorine or iodine.
The term “aryl” as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 12 carbons in the ring portion, preferably 6-10 carbons in the ring portion, such as phenyl, naphthyl or tetrahydronaphthyl.
The term “heterocycle” or “heterocyclic ring”, as used herein except where noted, represents a stable 5- to 7-memebered mono-heterocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O, and S, and wherein the nitrogen and sulfur heteroatom may optionally be oxidized. Especially useful are rings contain one nitrogen combined with one oxygen or sulfur, or two nitrogen heteroatoms. Examples of such heterocyclic groups include piperidinyl, pyrrolyl, pyrrolidinyl, imidazolyl, imidazlinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, homopiperidinyl, homopiperazinyl, pyridazinyl, pyrazolyl, and pyrazolidinyl, most preferably thiamorpholinyl, piperazinyl, and morpholinyl.
The term “heteroatom” is used herein to mean an oxygen atom (“O”), a sulfur atom (“S”) or a nitrogen atom (“N”). It will be recognized that when the heteroatom is nitrogen, it may form an NRaRb moiety, wherein Ra and Rb are, independently from one another, hydrogen or C1-4 alkyl, C2-4 aminoalkyl, C1-4 halo alkyl, halo benzyl, or R1 and R2 are taken together to form a 5- to 7-member heterocyclic ring optionally having O, S or NRc in said ring, where Rc is hydrogen or C1-4 alkyl.
The present invention is further directed to a methods of preparing compounds of the above Formula I, II III or III′. The compounds of this invention can be prepared by reactions described in Schemes 1-13.
Schemes 4 through 6 depict synthetic routes for forming benzoxazoles of the present invention.
Schemes 7, 8 and 9 depict synthetic routes for preparing indole derivatives and benzimidazole derivatives of the present invention.
Scheme 10 depicts a synthetic route for forming benzofuran derivatives of the present invention. Alternatively, benzofurans can be prepared via an intramolecular Wittig Route (Twyman, et al., Tetrahedron Lett 40:9383 (1999)) as set forth in Scheme 11.
Scheme 12 provides a synthetic route for parallel synthesis of benzofuran derivatives of the present invention.
Schemes 13 through 17 are directed to imidazo [1,2a] pyridine derivatives of the present invention.
Schemes 18 and 19 depict synthetic routes for forming benzopyrimidines of the present invention.
Shemes 21 through 23 are directed to imidazo[1,2a][1,3] diazepine derivatives of Formula III′.
When the compounds of this invention are to be used as imaging agents, they must be labeled with suitable radioactive halogen isotopes. Although 125I-isotopes are useful for laboratory testing, they will generally not be useful for actual diagnostic purposes because of the relatively long half-life (60 days) and low gamma-emission (30-65 Kev) of 125I. The isotope 123I has a half life of thirteen hours and gamma energy of 159 Ke V, and it is therefore expected that labeling of ligands to be used for diagnostic purposes would be with this isotope. Other isotopes which may be used include 131I (half life of 2 hours). Suitable bromine isotopes include 77Br and 76Br.
The radiohalogenated compounds of this invention lend themselves easily to formation from materials which could be provided to users in kits. Kits for forming the imaging agents can contain, for example, a vial containing a physiologically suitable solution of an intermediate of Formula I, II, III or III′ in a concentration and at a pH suitable for optimal complexing conditions. The user would add to the vial an appropriate quantity of the radioisotope, e.g., Na123I, and an oxidant, such as hydrogen peroxide. The resulting labeled ligand may then be administered intravenously to a patient, and receptors in the brain imaged by means of measuring the gamma ray or photo emissions therefrom.
Since the radiopharmaceutical composition according to the present invention can be prepared easily and simply, the preparation can be carried out readily by the user. Therefore, the present invention also relates to a kit, comprising:
-
- (1) A non-radiolabeled compound of the invention, the compound optionally being in a dry condition; and also optionally having an inert, pharmaceutically acceptable carrier and/or auxiliary substances added thereto; and
- (2) a reducing agent and optionally a chelator;
wherein ingredients (1) and (2) may optionally be combined; and
further wherein instructions for use with a prescription for carrying out the above-described method by reacting ingredients (1) and (2) with technetium-99m in the form of a pertechnetate solution may be optionally included.
Examples of suitable reducing agents and chelators for the above kit have been listed above. The pertechnetate solution can be obtained by the user from a molybdenum-technetium generator. Such generators are available in a number of institutions that perform radiodiagnostic procedures. As noted above the ingredients (1) and (2) may be combined, provided they are compatible. Such a monocomponent kit, in which the combined ingredients are preferably lyophilized, is excellently suitable to be reacted by the user with the pertechnetate solution in a simple manner.
When desired, the radioactive diagnostic agent may contain any additive such as pH controlling agents (e.g., acids, bases, buffers), stabilizers (e.g., ascorbic acid) or isotonizing agents (e.g., sodium chloride).
The term “pharmaceutically acceptable salt” as used herein refers to those carboxylate salts or acid addition salts of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term “salts” refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention. Also included are those salts derived from non-toxic organic acids such as aliphatic mono and dicarboxylic acids, for example acetic acid, phenyl-substituted alkanoic acids, hydroxy alkanoic and alkanedioic acids, aromatic acids, and aliphatic and aromatic sulfonic acids. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Further representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactiobionate and laurylsulphonate salts, propionate, pivalate, cyclamate, isethionate, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as, nontoxic ammonium, quaternary ammonium and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example, Berge S. M, et al., Pharmaceutical Salts, J. Pharm. Sci. 66:1-19 (1977) which is incorporated herein by reference.)
In the first step of the present method of imaging, a labeled compound of Formula I, II, III or III′ is introduced into a tissue or a patient in a detectable quantity. The compound is typically part of a pharmaceutical composition and is administered to the tissue or the patient by methods well known to those skilled in the art.
For example, the compound can be administered either orally, rectally, parenterally (intravenous, by intramuscularly or subcutaneously), intracistemally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments or drops), or as a buccal or nasal spray.
In a preferred embodiment of the invention, the labeled compound is introduced into a patient in a detectable quantity and after sufficient time has passed for the compound to become associated with amyloid deposits, the labeled compound is detected noninvasively inside the patient. In another embodiment of the invention, a labeled compound of Formula I, II, III or III′ is introduced into a patient, sufficient time is allowed for the compound to become associated with amyloid deposits, and then a sample of tissue from the patient is removed and the labeled compound in the tissue is detected apart from the patient. In a third embodiment of the invention, a tissue sample is removed from a patient and a labeled compound of Formula I, II, III or III′ is introduced into the tissue sample. After a sufficient amount of time for the compound to become bound to amyloid deposits, the compound is detected.
The administration of the labeled compound to a patient can be by a general or local administration route. For example, the labeled compound may be administered to the patient such that it is delivered throughout the body. Alternatively, the labeled compound can be administered to a specific organ or tissue of interest. For example, it is desirable to locate and quantitate amyloid deposits in the brain in order to diagnose or track the progress of Alzheimer's disease in a patient.
The term “tissue” means a part of a patient's body. Examples of tissues include the brain, heart, liver, blood vessels, and arteries. A detectable quantity is a quantity of labeled compound necessary to be detected by the detection method chosen. The amount of a labeled compound to be introduced into a patient in order to provide for detection can readily be determined by those skilled in the art. For example, increasing amounts of the labeled compound can be given to a patient until the compound is detected by the detection method of choice. A label is introduced into the compounds to provide for detection of the compounds.
The term “patient” means humans and other animals. Those skilled in the art are also familiar with determining the amount of time sufficient for a compound to become associated with amyloid deposits. The amount of time necessary can easily be determined by introducing a detectable amount of a labeled compound of Formulae I-III′ into a patient and then detecting the labeled compound at various times after administration.
The term “associated” means a chemical interaction between the labeled compound and the amyloid deposit. Examples of associations include covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-hydrophobic interactions, and complexes.
Those skilled in the art are familiar with the various ways to detect labeled compounds. For example, magnetic resonance imaging (MRI), positron emission tomography (PET), or single photon emission computed tomography (SPECT) can be used to detect radiolabeled compounds. The label that is introduced into the compound will depend on the detection method desired. For example, if PET is selected as a detection method, the compound must possess a positron-emitting atom, such as 11C or 18F.
The radioactive diagnostic agent should have sufficient radioactivity and radioactivity concentration which can assure reliable diagnosis. For instance, in case of the radioactive metal being technetium-99m, it may be included usually in an amount of 0.1 to 50 mCi in about 0.5 to 5.0 ml at the time of administration. The amount of a compound of Formulae I-III′ may be such as sufficient to form a stable chelate compound with the radioactive metal.
The thus formed chelate compound as a radioactive diagnostic agent is sufficiently stable, and therefore it may be immediately administered as such or stored until its use. When desired, the radioactive diagnostic agent may contain any additive such as pH controlling agents (e.g., acids, bases, buffers), stabilizers (e.g., ascorbic acid) or isotonizing agents (e.g., sodium chloride).
The imaging of amyloid deposits can also be carried out quantitatively so that the amount of amyloid deposits can be determined.
Preferred compounds for imaging include a radioisotope such as 123I, 125I, 131I, 18F, 76Br or 77Br.
The present invention is also directed at a method of imaging amyloid deposits. One of the key prerequisites for an in vivo imaging agent of the brain is the ability to cross the intact blood-brain barrier after a bolus iv injection. The compounds of this invention possess a core ring system comprised of various substituted, fused 5- and 6-member aromatic rings. Several compounds of this invention contain a benzothiazole core and are derivatives of thioflavins. These compounds contain no quaternary ammonium ion, therefore, they are relatively small in size, neutral and lipophilic (Partition Coefficient=70 and 312 for 3 and 6a, respectively).
To test the permeability through the intact blood-brain barrier several compounds of Formula I or III were injected into normal mice. Initial brain uptake of 3 and 6a in mice after an iv injection was 0.67 and 1.50% dose/organ, respectively (see Table 1). The brain uptake peaked at 60 min for both compounds with a maximum brain uptake of 1.57 and 1.89% dose/organ, respectively. The blood levels are relatively low throughout the time points evaluated. For this series of ligands, specific uptake in the brain is relatively high and the retention in the brain is long.
Another aspect of the invention is a method of inhibiting amyloid plaque aggregation. The present invention also provides a method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, by administering to a patient an amyloid inhibiting amount of a compound of the above Formula I, II, III or III′.
Those skilled in the art are readily able to determine an amyloid inhibiting amount by simply administering a compound of Formula I, II, III or III′ to a patient in increasing amounts until the growth of amyloid deposits is decreased or stopped. The rate of growth can be assessed using imaging as described above or by taking a tissue sample from a patient and observing the amyloid deposits therein. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is sufficient. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered and obvious to those skilled in the art are within the spirit and scope of the invention.
2-(4′-Dimethylaminophenyl)-6-bromobenzothiazole (1): (Stevens, M. F. G., et al., J. Med. Chem. 37:1689-1695 (1994); Stevens, M. F. G., et al., PCT Int. Appl. WO 19940830:47 (1995))
A mixture of 5-bromo-2-amino-benzenethiol (Mital, R. L. and Jain, S. K., J. Chem Soc (C): 2148 (1969); Lin, A.-J. and Kasina, S., J Heterocycl Chem 18:759 (1981)) (306 mg, 1.5 mmol) and 4-dimethylamino benzaldehyde (224 mg, 1.5 mmol) in DMSO was heated at 180° C. for 15 min. Water (10 mL) was added after the mixture was cooled down. The solid was collected by suction and recrystallized in ethyl acetate to give 340 mg of product (68%).
1H NMR (200 MHz, CDCl3): δ 3.06 (s, 6H), 6.74 (d, J=9.0 Hz, 2H), 7.52 (d,d, J=8.7, 2.0 Hz, 1H), 7.82 (d, J=8.6 Hz,1H), 7.93 (d, J=8.8 Hz, 2H), 7.95 (s,1H).
HRMS: m/z Calcd for C5H14BrN2S(MH+): 333.0061; Found: 333.0072.
2-(4′-Dimethylaminophenyl)-6-tribytylstannylbenzothiazole (2): To a solution of 2-(4′-dimethylaminophenyl)-6-bromobenzothiazole (16a)(60 mg, 0.18 mmol) in 1,4-dioxane (2 mL), toluene (2 mL) and triethylamine (2 mL) was added (Bu3Sn)2 (0.2 mL) followed by Pd(Ph3P)4 (20 mg). The mixture was stirred at 90° C. overnight. Solvent was removed and the residue was purified by PTLC (Hex:EtOAc, 6:1) to give 33 mg of product (yield 33.6%).
1H NMR (200 MHz, CDCl3): δ 0.90 (t, J=7.1 Hz, 9H), 1.10 (t, J=8.0 Hz, 6H), 1.34 (hex, J=7.3 Hz, 6H), 1.57 (m, 6H), 3.05 (s, 6H), 6.74 (d, J=9.0 Hz, 2H), 7.50 (d,d, J=7.9, 0.9 Hz, 1H), 7.93 (s,1H), 7.95 (d, J=8.5 Hz,1H), 7.97 (d, J=9.0 Hz, 2H).
HRMS: m/z Calcd for C27H41N2SSn(MH+): 545.2012; Found: 545.2035.
2-(4′-Dimethylaminophenyl)-6-iodobenzothiazole, (3): To a solution of 2 (45 mg, 0.08 mmol) in CHCl3 (10 mL) was added a solution of iodine (1 mL, 1M in CHCl3) dropwise at RT until the color maintaining unchanged. The resulting mixture was stirred at RT for 10 min. NaHSO3 solution (2 mL, 5% in water) and KF (1 mL, 1M in MeOH) were added successively. The mixture was stirred for 5 min and the organic phase was separated. The aqueous phase was extracted with CH2Cl2 and the combined organic phases was dried over Na2SO4, filtered and concentrated to give crude product which was purified by PTLC (Hex:EtOAc, 6:1) to give 9 mg of the desired product (yield 29%). 1H NMR (200 MHz, CDCl3): δ 3.06 (s, 6H), 6.73 (d, J=9.0 Hz, 2H), 7.69 (s, 1H), 7.70 (s, 1H), 7.93 (d, J=9.0 Hz, 2H), 8.15 (s, 1H).
HRMS: m/z Calcd for C5H15N2IS(MH+): 380.9922; Found: 380.9914.
Anal. (C5H14N3′S): C, H, N.
2-[4′-(4″-Methylpiperazin-1-yl)-phenyl]-6-bromobenzothiazole (4): The procedure described above to prepare 1 was employed to give 57.2% of product 4 from 4-(4-methylpiperazin-1-yl)benzaldehyde (Tanaka, A., et al., J. Med. Chem. 41:2390 (1998)) (204 mg, 1 mmol) and 5-bromo-2-amino-benzenethiol (204 mg, 1 mmol).
1H NMR (200 MHz, CDCl3): δ 2.38 (s,3H),2.60 (t, J=5.0 Hz,4H),3.38 (t, J=5.0 Hz, 4H), 6.96 (d, J=8.9 Hz, 2H), 7.54 (d,d, J=8.5, 1.9 Hz, 1H), 7.83 (d, J=8.5 Hz,1H), 7.95 (d, J=8.9 Hz, 2H), 7.98 (s,1H).
HRMS: m/z Calcd for C18H19BrN3S(MH+): 388.0483; Found: 388.0474.
2-4′-(4″-Methylpiperazin-1-yl)-phenyl]-6-tributylstannyl benzothiazole (5): The procedure described above to prepare 2 was employed, 5 was obtained in 23% yield from 4.
1H NMR (200 MHz, CDCl3): δ 0.89 (t, J=7.2 Hz, 9H), 1.06 (t, J=8.2 Hz, 6H), 1.30 (hex, J=7.3 Hz, 6H), 1.57 (pen, J=7.2 Hz, 6H), 2.38 (s, 3H), 2.60 (m, 4H), 3.36 (t, J=5.0 Hz, 4H), 6.96 (d, J=8.9 Hz, 2H), 7.52 (d, J=7.9 Hz, 1H), 7.93 (s,1H), 7.95 (d, J=7.9 Hz,1H), 7.98 (d, J=8.9 Hz, 2H).
HRMS: m/z Calcd for C30H46N3SSn(MH+): 600.2434; Found: 600.2449.
2-[4′-(4″-Methylpiperazin-1-yl)-phenyl]-6-iodobenzothiazole, (6): The same reaction as described above to prepare 3 was employed, 6 was obtained in 36% yield from 5.
1H NMR (200 MHz, CDCl3): δ 2.42 (s, 3H), 263 (t, J=4.8 Hz, 4H), 3.40 (t, J=4.9 Hz, 4H), 6.95 (d, J=9.0 Hz, 2H), 7.71 (s,1H), 7.72 (s,1H), 7.95 (d, J=8.9 Hz, 2H), 8.17 (t, J=1.0 Hz, 1H).HRMS: m/z Calcd for C8N19N3IS(MH+): 436.0344; Found: 436.0364. Anal. (C18H18N3SI): C, H, N.
6-Bromo-2-(4′-Dimethylamino-)Phenyl-Imidazo [1,2-a] pyridine (17)
A mixture of 2-bromo-4′-dimethylaminoacetophenone, (968 mg, 4 mmol) and 2-amino-5-bromo-pyridine (692 mg, 4 mmol) in EtOH (25 mL) was stirred under reflux for 2 hr. NaHCO3 (500 mg) was added after the mixture was cooled down. The resulting mixture was stirred under reflux for 4.5 hr. The mixture was cooled down, filtered to give 655 mg of product, 17 (52%).
1H NMR (200 MHz, CDCl3,δ): 3.00 (s, 6H), 6.78 (d, J=8.7 Hz, 2H), 7.17 (d,d, J=9.5, 1.7 Hz, 1H), 7.49 (d, J=9.5 Hz, 1H), 7.69 (s, 1H), 7.80 (d, J=8.7 Hz, 2H), 8.21 (d,d, J=1.7, 0.8 Hz, 1H). Anal.3a, (C15H14BrN3)
6-Tributylstannyl-2-(4′-dimethylamino-)phenyl-imidazo[1,2-a]pyridine (18).
To a solution of 6-bromo-2-(4′-dimethylamino-)phenyl-imidazo [1,2-a]pyridine, 17, (80 mg, 0.26 mmol) in 1,4-dioxane (10 mL) and triethylamine (2 mL) was added (Bu3Sn)2 (0.2 mL) in neat followed by Pd(Ph3P)4 (20 mg). The mixture was stirred at 90° C. overnight. Solvent was removed and the residue was purified by PTLC (Hex:EtOAc=1:1 as developing solvent) to give 23 mg of product, 18 (17%).
1H NMR (200 MHz, CDCl3,δ): 0.90 (t, J=7.2 Hz, 9H), 1.10 (t, J=8.0 Hz, 6H), 1.33 (hex, J=7.1 Hz, 6H), 1.54 (pen, J=7.2 Hz, 6H), 3.00 (s, 6H), 6.78 (d, J=8.9 Hz, 2H), 7.11 (d, J=8.8 Hz, 1H), 7.57 (d, J=8.8 Hz, 1H), 7.71 (s, 1H), 7.84 (d, J=8.8 Hz, 2H), 7.95 (d, J=0.8 Hz, 1H). HRMS: m/z Calcld for C27H42N3Sn(M++H): 528.2400; Found: 528.2402. Anal.4, (C27H41N3Sn.2H2O)
6-Odo-2-(4′-Dimethylamino-)Phenyl-Imidazo[1,2-a] pyridine, IMPY, (16)
A mixture of 2-bromo-4′-dimethylaminoacetophenone, (484 mg, 2 mmol) and 2-amino-5-iodo-pyridine (440 mg, 2 mmol) in EtOH (25 mL) was stirred under reflux for 2 hr. NaHCO3 (250 mg) was added after the mixture was cooled down. The resulting mixture was stirred under reflux for 4 hr. The mixture was cooled down, filtered to give 348 mg of product, 3b (48%).
1H NMR (200 MHz, CDCl3,δ): 3.00 (s, 6H), 6.77 (d, J=8.8 Hz, 2H), 7.27 (d,d, J=9.4, 1.5 Hz, 1H), 7.38 (d, J=9.5 Hz, 1H), 7.66 (s, 1H), 7.79 (d, J=8.8 Hz, 2H), 8.32 (d, J=0.7 Hz, 1H). Anal.3b, (C15H14IN3).
The compound, [125I]18, was prepared using iododestannylation reactions with tributyltin precursor 17. Hydrogen peroxide (50 μL, 3% w/v) was added to a mixture of 50 μL of the correspondent tributyltin precursor (1 μg/μL EtOH), 50 μL of 1N HCl and [125/123I]NaI (1-5 mCi) in a sealed vial. The reaction was allowed to proceed for 10 min at room temperature and terminated by addition of 100 μL of sat. NaHSO3. The reaction mixture was either directly extracted (styrylbenzenes) with ethylacetate (3×1 mL) or extracted after neutralization with saturated sodium bicarbonate solution (thioflavins). The combined extracts were evaporated to dryness. For styrylbenzenes the residues were dissolved in 100 μL of EtOH and purified by HPLC using a reverse phase column (Waters ubondpad, 3.9×300 mm) with an isocratic solvent of 65% acetonitrile-35% trifluoroacetic acid (0.1%) in a flow rate of 0.8 mL/min. Thioflavins were purified on a C4 column (Phenomenex Inc, Torrance, Calif.) eluted with an isocratic solvent of 80% acetonitrile-20% 3,3-dimethyl-glutaric acid (5 mM, pH 7.0) in a flow rate of 0.8 mL/min. The desired fractions containing the product were collected, condensed and re-extracted with ethylacetate. The no-carrier-added products were evaporated to dryness and re-dissolved in 100% EtOH (1 μCi/μL), The final 125I 18, with a specific activity of 2,200 Ci/mmole and a greater than 95% radiochemical purity, were stored at −20° C. up to 6 weeks for in vitro binding and autoradiography studies.
Partition coefficients were measured by mixing the [125I] tracer with 3 g each of 1-octanol and buffer (0.1 M phosphate, pH 7.4) in a test tube. The test tube was vortexed for 3 min at room temperature, followed by centrifugation for 5 min. Two weighed samples (0.5 g each) from the 1-octanol and buffer layers were counted in a well counter. The partition coefficient was determined by calculating the ratio of cpm/g of 1-octanol to that of buffer. Samples from the 1-octanol layer were re-partitioned until consistent partitions of coefficient values were obtained. The measurement was done in triplicate and repeated three times.
The solid forms of peptides Aβ(1-40) and Aβ(1-42) were purchased from Bachem (King of Prussia, P.A.). Aggregation of peptides were carried out by gently dissolving the peptide [0.5 mg/mL for Aβ(I-40) and 0.25 mg/mL for Aβ(1-42) in a buffer solution (pH 7.4) containing 10 mM sodium phosphate and 1 mM EDTA. The solutions were incubated at 37° C. for 36-42 h with gentle and constant shaking. Binding studies were carried out in 12×75 mm borosilicate glass tubes according to the procedure described with some modifications (Klunk, W. E., et al., Biol. Psychiatry 35:627 (1994)). Aggregated fibrils (10-50 nM in the final assay mixture) were added to the mixture containing 50 ml of radioligands (0.01-0.5 nM) in 40% EtOH and 10% EtOH in a final volume of 1 mL for saturation studies. Nonspecific binding was defined in the presence of 2 mM thioflavin T for thioflavins. For inhibition studies, 1 mL of the reaction mixture contained 40 ml of inhibitors (10-5-10-10 M in 10% EtOH) and 0.05 nM radiotracer in 40% EtOH. The mixture was incubated at room temperature for 3 h and the bound and the free radioactivity were separated by vacuum filtration through Whatman GF/B filters using a Brandel M-24R cell harvester followed by 2×3 mL washes of 10% ethanol at room temperature. Filters containing the bound I-125 ligand were counted in a gamma counter (Packard 5000) with 70% counting efficiency. The results of saturation and inhibition experiments were subjected to nonlinear regression analysis using software EBDA52 by which Kd and Ki values were calculated. Additional Ki values for compounds of the invention are provided in FIG. 1A and FIG. 1B .
TABLE 1 |
Inhibition constants (Ki, nM) of compounds on ligand binding to |
aggregates of Aβ(1-40) and Aβ(1-42) at 25° C. |
Aggregates of Aβ | Aggregates of Aβ | |
(1-40) | (1-42) | |
Compounds | vs[125I]3 | vs[125I]3 |
Chrysamine G | >1,000 | >2,000 |
Thioflavin T | 116 ± 20 | 294 ± 40 |
1 | 1.9 ± 0.3 | 0.8 ± 0.3 |
4 | 1.6 ± 0.5 | 5.0 ± 0.8 |
3 | 0.9 ± 0.2 | 2.2 ± 0.4 |
6a | 5.4 ± 0.7 | 6.4 ± 0.7 |
Values are the mean ± SEM of three independent experiments, each in duplicates. |
While under ether anesthesia, 0.15 mL of a saline solution containing labeled agents (5-10 mCi) was injected directly into the tail vein of ICR mice (2-3 month-old, average weight 20-30 g). The mice were sacrificed by cardiac excision at various time points post injection. The organs of interest were removed and weighed, and the radioactivity was counted with an automatic gamma counter (Packard 5000). The percentage dose per organ was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. Total activities of blood and muscle were calculated under the assumption that they were 7% and 40% of the total body weight, respectively.
TABLE 2 | |||||
Organ | 2 min | 30 min | 60 min | 6 h | 24 h |
[125I] Compound 3 (PC = 70) |
Blood | 15.74 ± 6.06 | 3.26 ± 0.05 | 3.79 ± 0.19 | 1.44 ± 0.05 | 0.29 ± 0.09 |
Heart | 1.79 ± 0.39 | 0.20 ± 0.01 | 0.17 ± 0.02 | 0.05 ± 0.01 | 0.01 ± 0.00 |
Liver | 31.62 ± 2.38 | 10.93 ± 2.34 | 9.21 ± 3.05 | 1.52 ± 0.30 | 0.30 ± 0.07 |
Brain | 0.67 ± 0.11 | 0.97 ± 0.29 | 1.57 ± 0.24 | 0.65 ± 0.11 | 0.04 ± 0.01 |
[125I] Compound 6a (PC = 312) |
Blood | 8.02 ± 0.82 | 5.15 ± 0.23 | 4.16 ± 0.28 | 1.49 ± 0.26 | 0.41 ± 0.09 |
Heart | 2.19 ± 0.43 | 0.69 ± 0.02 | 0.66 ± 0.06 | 0.22 ± 0.06 | 0.08 ± 0.01 |
Liver | 28.84 ± 3.77 | 21.22 ± 5.86 | 17.20 ± 2.49 | 5.79 ± 1.24 | 3.05 ± 0.87 |
Brain | 1.50 ± 0.10 | 1.59 ± 0.19 | 1.89 ± 0.43 | 1.08 ± 0.08 | 0.91 ± 0.08 |
[125I] Compound 8 (PC = 124) |
Blood | 4.31 ± 0.34 | 2.80 ± 0.45 | 2.94 ± 0.18 | 2.23 ± 0.53 | 1.68 ± 0.56 |
Heart | 1.20 ± 0.18 | 0.19 ± 0.05 | 0.11 ± 0.02 | 0.05 ± 0.00 | 0.02 ± 0.00 |
Liver | 25.04 ± 2.45 | 17.45 ± 2.01 | 5.57 ± 0.39 | 1.08 ± 0.11 | 0.42 ± 0.08 |
Brain | 1.43 ± 0.23 | 2.08 ± 0.03 | 1.26 ± 0.10 | 0.12 ± 0.02 | 0.01 ± 0.00 |
[125I] Compound 19 (PC = 100) |
Organ | 2 min | 30 min | 1 hr | 2 hr | 6 hr | 24 hr |
BLOOD | 6.41 ± 0.77 | 2.44 ± 0.36 | 2.50 ± 0.11 | 1.82 ± 0.21 | 1.40 ± 0.27 | 0.18 ± 0.02 |
HEART | 0.79 ± 0.14 | 0.16 ± 0.02 | 0.12 ± 0.02 | 0.08 ± 0.01 | 0.04 ± 0.01 | 0.01 ± 0.00 |
MUSCLE | 13.81 ± 3.44 | 6.08 ± 0.59 | 5.03 ± 1.03 | 2.96 ± 0.84 | 1.46 ± 0.42 | 0.27 ± 0.11 |
LUNG | 1.56 ± 0.33 | 0.31 ± 0.07 | 0.34 ± 0.08 | 0.20 ± 0.05 | 0.12 ± 0.05 | 0.05 ± 0.03 |
KIDNEY | 4.75 ± 0.49 | 1.51 ± 0.27 | 1.17 ± 0.29 | 0.53 ± 0.05 | 0.25 ± 0.05 | 0.05 ± 0.01 |
SPLEEN | 0.40 ± 0.06 | 0.09 ± 0.02 | 0.08 ± 0.01 | 0.05 ± 0.01 | 0.04 ± 0.01 | 0.01 ± 0.00 |
LIVER | 20.88 ± 2.63 | 6.32 ± 0.55 | 5.88 ± 0.85 | 2.90 ± 0.21 | 1.54 ± 0.08 | 0.61 ± 0.11 |
SKIN | 5.72 ± 0.90 | 4.69 ± 1.06 | 4.28 ± 0.25 | 3.14 ± 0.51 | 2.19 ± 0.63 | 0.22 ± 0.06 |
BRAIN | 2.88 ± 0.25 | 0.26 ± 0.00 | 0.21 ± 0.03 | 0.14 ± 0.03 | 0.06 ± 0.02 | 0.02 ± 0.00 |
% dose/organ, average of 3 mice ± SD; | ||||||
Average organ weights are: blood, 2 g; muscle, 12 g; liver, g; brain 0.4 g, from which the % dose/g value for each organ or tissue can be calculated. | ||||||
*(% dose/organ, avg of 3 or 4 mice ± SD) |
Having now fully described this invention, it will be understood to those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications, and publications cited herein are fully incorporated by reference herein in their entirety.
Claims (24)
1. A compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein
R3 is Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br of or Sn(alkyl)3; and
R1 and R2 are independently hydrogen, C1-4 alkyl, C2-4 aminoalkyl, C1-4 haloalkyl, haloarylalkyl, or R1 and R2 are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S, or NR5 in said ring, where
R5 is hydrogen or C1-4 alkyl.
2. A The compound of claim 1 , wherein R3 is 125I, 131I, 123I, 18F, 76Br, or 77Br.
3. A The compound of claim 2 , wherein:
R1 and R 2 are independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, or 4-fluorobenzyl.
4. A The compound of claim 1 , wherein:
R5R3 is 123I or 125I; and
R1 and R2 are both methyl.
5. A The compound of claim 1 , wherein:
R3 is Sn(alkyl)3; and
R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, or 4-fluorobenzyl.
6. A The compound of claim 5 , wherein R1 and R2 are C1-4 alkyl.
7. A The compound of claim 6 , wherein R1 and R2 are methyl.
8. A compound of Formula III′:
or a pharmaceutically acceptable salt thereof, wherein
A, B, and D are CH or N,
provided that no more than two of A, B, and D is N;
R3 is Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br, haloalkyl, Sn(alkyl)3 or —L—Ch;
R1 and R2 are independently hydrogen, C1-4 alkyl, C2-4 aminoalkyl, C1-4 haloalkyl, haloarylalkyl, —L—Ch, or R1 and R2 are taken together with the nitrogen to which they are attached to form a 5- to 7-member heterocyclic ring optionally having O, S or NR5 in said ring, where
R5 is hydrogen or C1-4 alkyl;
L is a covalent bond or linking group, such as —(CH2)n—, or —(CH2)n—C(O)—
where
n is 0-5; and
Ch is a tetradentate ligand capable of complexing with a metal;
with the proviso that only one of R1, R2, and R3 can be is —L—Ch.
9. A The compound of claim 8 , wherein A and B are CH; and D is N.
10. A The compound of claim 8 , wherein A and D are CH; and B is N.
11. A The compound of claim 8 , wherein B and D are CH; and A is N.
12. A The compound of claim 9 , wherein R1 and R2 are independently hydrogen or C1-4 alkyl.
13. A The compound of claim 12 , wherein R1 and R2 are both methyl.
14. A The compound of claim 13 , wherein R3 is Br, I, F, 125I, 131I, 123I, 18F, 76Br, 77Br, 18F/fluoro(C1-5)alkyl or Sn(alkyl)3.
15. A The compound of claim 14 , wherein R3 is 18F/fluoromethyl, 18F/fluoroethyl, 18F/fluoropropyl, 18F/fluorobutyl, or 18F/fluoropentyl.
16. A The compound of claim 9 , wherein R3 is L-Ch.
19. A The compound of claim 18 , wherein R1 and R2 are independently hydrogen or C1-4 alkyl.
20. A The compound of claim 19 , wherein R1 and R2 are both methyl.
21. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable excipient or diluent.
22. A diagnostic composition for imaging amyloid deposits, comprising a radiolabeled compound of claim 2 and a pharmaceutically acceptable excipient or diluent.
23. A method of inhibiting reducing amyloid plaque aggregation in a mammal, comprising administering a composition of claim 21 in an amount effective to inhibit reduce amyloid plaque aggregation.
24. A method of imaging amyloid deposits, comprising:
a. introducing into a mammal a detectable quantity of a diagnostic composition of claim 22 ; and
b. allowing sufficient time for the radiolabeled compound to become associated with amyloid deposits; and
c. detecting the radiolabeled compound associated with one or more amyloid deposits.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/550,853 USRE44338E1 (en) | 2001-04-23 | 2012-07-17 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28528201P | 2001-04-23 | 2001-04-23 | |
US10/127,678 US6696039B2 (en) | 2001-04-23 | 2002-04-23 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US13/550,853 USRE44338E1 (en) | 2001-04-23 | 2012-07-17 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/127,678 Reissue US6696039B2 (en) | 2001-04-23 | 2002-04-23 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE44338E1 true USRE44338E1 (en) | 2013-07-02 |
Family
ID=23093574
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/127,678 Expired - Lifetime US6696039B2 (en) | 2001-04-23 | 2002-04-23 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US10/739,217 Expired - Lifetime US6946116B2 (en) | 2001-04-23 | 2003-12-19 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US11/203,429 Expired - Lifetime US7425318B2 (en) | 2001-04-23 | 2005-08-15 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US13/550,885 Expired - Lifetime USRE44354E1 (en) | 2001-04-23 | 2012-07-17 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US13/550,853 Expired - Lifetime USRE44338E1 (en) | 2001-04-23 | 2012-07-17 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/127,678 Expired - Lifetime US6696039B2 (en) | 2001-04-23 | 2002-04-23 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US10/739,217 Expired - Lifetime US6946116B2 (en) | 2001-04-23 | 2003-12-19 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US11/203,429 Expired - Lifetime US7425318B2 (en) | 2001-04-23 | 2005-08-15 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US13/550,885 Expired - Lifetime USRE44354E1 (en) | 2001-04-23 | 2012-07-17 | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
Country Status (12)
Country | Link |
---|---|
US (5) | US6696039B2 (en) |
EP (1) | EP1381604B1 (en) |
JP (1) | JP4317955B2 (en) |
KR (1) | KR20040058111A (en) |
CN (1) | CN100422180C (en) |
AT (1) | ATE349446T1 (en) |
AU (1) | AU2002258915B2 (en) |
CA (1) | CA2444214A1 (en) |
DE (1) | DE60217090T2 (en) |
ES (1) | ES2274973T3 (en) |
TW (1) | TWI245764B (en) |
WO (1) | WO2002085903A2 (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544511B2 (en) * | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
GB0018473D0 (en) * | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
US7270800B2 (en) | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
RU2324686C2 (en) * | 2000-08-24 | 2008-05-20 | Юнивесити Оф Питсбэг | AMYLOID-BINDING THIOFLAVIN DERIVATIVES, METHOD OF in vivo DETECTION OF AMYLOID DEPOSIT AND METHOD OF DIAGNOSTICS OF ALZHEIMER'S DISEASE |
US6696039B2 (en) | 2001-04-23 | 2004-02-24 | Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
AU2003212490A1 (en) * | 2002-02-13 | 2003-09-04 | Amersham Plc | Benzothiazole derivatives for in vivo imaging of amyloid plaques |
AU2003293409A1 (en) | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
RU2005126421A (en) * | 2003-01-22 | 2006-02-10 | Дзе Дженерал Хоспитал Корпорейшн (Us) | AMYLO-BINDING METAL-CHELATING AGENTS |
BRPI0408274B8 (en) * | 2003-03-14 | 2021-05-25 | Univ Pittsburgh | amyloid binding compounds and pharmaceutical composition |
CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
GB0307855D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
WO2004100998A2 (en) | 2003-05-07 | 2004-11-25 | General Electric Company | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
US8236282B2 (en) | 2003-08-22 | 2012-08-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Benzothiazole derivative compounds, compositions and uses |
US20050049487A1 (en) * | 2003-08-26 | 2005-03-03 | Johnson Bruce Fletcher | Compounds and kits for preparing imaging agents and methods of imaging |
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
JP5311739B2 (en) * | 2004-03-18 | 2013-10-09 | サントリーホールディングス株式会社 | 3- [3- (Benzoylamido) benzyloxy] aspartic acid derivative having radioactive label group and method for producing the same |
AU2005270026A1 (en) * | 2004-07-02 | 2006-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies |
CN101060865B (en) * | 2004-07-02 | 2011-10-05 | 匹兹堡大学高等教育联邦体系 | A method of diagnosing prodromal forms of diseases associated with amyloid deposition |
WO2006026184A2 (en) * | 2004-08-20 | 2006-03-09 | Washington University | Blood brain barrier permeation peptides |
CN101084303A (en) | 2004-11-17 | 2007-12-05 | 神经干公司 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
JP2008546804A (en) * | 2005-06-24 | 2008-12-25 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Radiolabeled PEGylation of ligands for use as contrast agents |
US7666886B2 (en) * | 2005-07-15 | 2010-02-23 | The Regents Of The University Of California | Compounds and methods for the diagnosis and treatment of amyloid associated diseases |
EP1928237A4 (en) | 2005-09-02 | 2011-03-09 | Abbott Lab | Novel imidazo based heterocycles |
US20080219922A1 (en) * | 2005-09-12 | 2008-09-11 | Goodman Mark M | Alzheimer's Disease Imaging Agents |
WO2007070173A2 (en) † | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
WO2007063946A1 (en) | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
JPWO2007069565A1 (en) * | 2005-12-12 | 2009-05-21 | 小野薬品工業株式会社 | Bicyclic heterocyclic compounds |
CA2636929A1 (en) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
TW200736252A (en) | 2006-01-27 | 2007-10-01 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
US7700616B2 (en) * | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
EP2019103B1 (en) | 2006-05-19 | 2011-11-30 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
CA2655826A1 (en) | 2006-06-21 | 2007-12-27 | Nihon Medi-Physics Co., Ltd. | Novel compound having affinity for amyloid |
JPWO2008056481A1 (en) * | 2006-11-09 | 2010-02-25 | 日本メジフィジックス株式会社 | Radiodiagnostic agent |
WO2008059714A1 (en) * | 2006-11-17 | 2008-05-22 | Nihon Medi-Physics Co., Ltd. | Novel compounds with affinity for amyloid |
KR20090083414A (en) | 2006-11-30 | 2009-08-03 | 니혼 메디피직스 가부시키가이샤 | Novel compound having affinity for amyloid |
US20100092385A1 (en) * | 2007-01-22 | 2010-04-15 | Astrazeneca Ab | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives |
TWI406674B (en) | 2007-02-13 | 2013-09-01 | Nihon Mediphysics Co Ltd | Method for manufacturing diagnostic radiographic diagnostic agents |
EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
TW200901998A (en) | 2007-03-06 | 2009-01-16 | Astrazeneca Ab | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes |
CA2680055A1 (en) * | 2007-03-06 | 2008-09-12 | Astrazeneca Ab | Novel 2-heteroaryl substituted indoles 695 |
FR2913886B1 (en) * | 2007-03-22 | 2012-03-02 | Guerbet Sa | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE |
WO2008134618A2 (en) * | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
KR20100091965A (en) * | 2007-10-24 | 2010-08-19 | 니혼 메디피직스 가부시키가이샤 | Novel compound having affinity for amyloid |
US8399672B2 (en) | 2007-10-26 | 2013-03-19 | Nihon Medi-Physics Co., Ltd. | Compound having affinity for amyloid |
WO2009057578A1 (en) | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | Utilization of novel compounds with amyloid affinity and method of producing the same |
CA2704137A1 (en) * | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
AU2008319984A1 (en) * | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
EP2218463A1 (en) * | 2007-10-30 | 2010-08-18 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
PL2247558T3 (en) | 2008-02-14 | 2022-05-02 | Eli Lilly And Company | Novel imaging agents for detecting neurological dysfunction |
US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
US20100331676A1 (en) * | 2008-02-27 | 2010-12-30 | Avid Radiopharmaceuticals, Inc. | Gamma probe detection of amyloid plaque using radiolabeled a-beta binding compounds |
AU2009225407B2 (en) * | 2008-03-21 | 2013-09-05 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders |
JP5603855B2 (en) * | 2008-04-04 | 2014-10-08 | アビッド レディオファーマシューティカルズ、インク. | Imaging neurodegenerative diseases with radiopharmaceuticals |
US8409419B2 (en) | 2008-05-21 | 2013-04-02 | Paul R. Kruesi | Conversion of carbon to hydrocarbons |
WO2009146388A1 (en) | 2008-05-28 | 2009-12-03 | The Trustees Of Columbia University In The City Of New York | Voxel-based methods for assessing subjects using positron emission tomography |
JP2011521959A (en) * | 2008-05-30 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | New substituted indole |
US8530483B2 (en) | 2008-05-30 | 2013-09-10 | Merck Sharp & Dohme Corp. | Substituted azabenzoxazoles |
AU2009253046A1 (en) * | 2008-05-30 | 2009-12-03 | Foster Wheeler Energia Oy | Method of and system for generating power by oxyfuel combustion |
EP2323697A2 (en) | 2008-07-24 | 2011-05-25 | Siemens Medical Solutions USA, Inc. | Imaging agents useful for identifying ad pathology |
EP2344877A4 (en) * | 2008-09-30 | 2014-09-10 | Univ Case Western Reserve | Molecular probes for imaging of myelin |
US20100145194A1 (en) * | 2008-11-13 | 2010-06-10 | Avid Radiopharmaceuticals, Inc. | Histogram-based analysis method for the detection and diagnosis of neurodegenerative diseases |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
EP2218464A1 (en) * | 2009-02-11 | 2010-08-18 | Technische Universität München | Compounds for non-invasive measurement of aggregates of amyloid peptides |
FR2942227B1 (en) | 2009-02-13 | 2011-04-15 | Guerbet Sa | USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION |
US8491869B2 (en) | 2009-03-23 | 2013-07-23 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
CU23844B1 (en) | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | PROCEDURE FOR OBTAINING NEW DERIVATIVES OF NAFTALENE FOR THE LIVE DIAGNOSIS OF ALZHEIMER'S DISEASE |
EP2543666A4 (en) | 2010-03-01 | 2013-01-09 | Nihon Mediphysics Co Ltd | Radioactive iodine labeled organic compound or salt thereof |
CA2806904C (en) | 2010-07-28 | 2018-11-27 | Neuralstem, Inc. | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
WO2012051170A2 (en) | 2010-10-12 | 2012-04-19 | Mayo Foundation For Medical Education And Research | Imaging of meningiomas using phingylbenzothiazole, stilbene, or biphenylalkyne derivatives |
RU2013125326A (en) * | 2010-11-16 | 2014-12-27 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | HETEROCYCLIC COMPOUNDS AS PROBES FOR VISUALIZING TAU PATHOLOGY |
FR2968999B1 (en) | 2010-12-20 | 2013-01-04 | Guerbet Sa | CHELATE NANOEMULSION FOR MRI |
TWI528977B (en) * | 2011-05-20 | 2016-04-11 | Nihon Mediphysics Co Ltd | New amyloid affinity products |
ES2619830T3 (en) | 2011-06-24 | 2017-06-27 | Nihon Medi-Physics Co., Ltd. | New compound with amyloid affinity |
FR2980364B1 (en) | 2011-09-26 | 2018-08-31 | Guerbet | NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS |
WO2013082508A1 (en) * | 2011-12-02 | 2013-06-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment and analysis of neurological disorders |
US20150157744A1 (en) | 2012-06-27 | 2015-06-11 | Geoffrey B. Johnson | Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives |
CN109846862A (en) | 2012-10-25 | 2019-06-07 | 通用医疗公司 | The combination treatment for treating Alzheimer disease and related disease |
US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
CN103073520B (en) * | 2012-12-24 | 2014-10-08 | 湖南大学 | Method for synthesizing 2-phenyl benzothiazole and derivative thereof |
FR3001154B1 (en) | 2013-01-23 | 2015-06-26 | Guerbet Sa | MAGNETO-EMULSION VECTORIZED |
EP2953970A4 (en) | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | Transthyretin antibodies and uses thereof |
EP2991983B1 (en) * | 2013-04-29 | 2017-03-01 | F. Hoffmann-La Roche AG | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
EP3049411B1 (en) | 2013-09-26 | 2017-04-26 | F. Hoffmann-La Roche AG | Imidazo[1,2-a]pyridin-7-amines as imaging tools |
JP2016534063A (en) | 2013-10-22 | 2016-11-04 | ザ ジェネラル ホスピタル コーポレイション | Cromolyn derivatives and related imaging and treatment methods |
US9750769B2 (en) | 2014-10-20 | 2017-09-05 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
EP3384960B1 (en) * | 2015-12-30 | 2019-06-05 | Neuboron Medtech Ltd. | NEUTRON CAPTURE THERAPY SYSTEM FOR ELIMINATING AMYLOID ß-PROTEIN |
WO2017114317A1 (en) * | 2015-12-30 | 2017-07-06 | 南京中硼联康医疗科技有限公司 | Compound for specific binding with β amyloid protein |
KR20190044647A (en) | 2016-08-31 | 2019-04-30 | 더 제너럴 하스피탈 코포레이션 | In neuro-inflammation associated neurodegenerative diseases, macrophages / microglia |
KR20210070232A (en) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | Powdered Formulation of Cromolin Sodium and Ibuprofen |
JP6831802B2 (en) * | 2018-01-12 | 2021-02-17 | 上海富吉医療器械有限公司Shanghai Chartwell Medical Instrument Co., Ltd. | Radionuclide-labeled compound and imaging agent containing it |
CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
KR102240400B1 (en) * | 2020-11-19 | 2021-04-15 | 한국원자력연구원 | Water soluble compound for detection of beta-amyloid |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006469A1 (en) | 1993-08-28 | 1995-03-09 | Cancer Research Campaign Technology Limited | Benzazole compounds for use in therapy |
EP0659418A1 (en) | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | 2-Phenyl-3-azoylbenzothiophene for treating Alzheimer's disease |
WO1997041856A1 (en) | 1996-05-08 | 1997-11-13 | Massachusetts Institute Of Technology | ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) |
WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
WO1999024394A2 (en) | 1997-11-06 | 1999-05-20 | University Of Pittsburgh | Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
US6037473A (en) | 1997-11-13 | 2000-03-14 | Haarmann & Reimer Gmbh | Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation |
US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
WO2002085903A2 (en) | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
-
2002
- 2002-04-23 US US10/127,678 patent/US6696039B2/en not_active Expired - Lifetime
- 2002-04-23 CN CNB028086708A patent/CN100422180C/en not_active Expired - Fee Related
- 2002-04-23 AU AU2002258915A patent/AU2002258915B2/en not_active Ceased
- 2002-04-23 ES ES02728893T patent/ES2274973T3/en not_active Expired - Lifetime
- 2002-04-23 WO PCT/US2002/012626 patent/WO2002085903A2/en active IP Right Grant
- 2002-04-23 DE DE60217090T patent/DE60217090T2/en not_active Expired - Lifetime
- 2002-04-23 TW TW091108360A patent/TWI245764B/en not_active IP Right Cessation
- 2002-04-23 JP JP2002583430A patent/JP4317955B2/en not_active Expired - Fee Related
- 2002-04-23 AT AT02728893T patent/ATE349446T1/en not_active IP Right Cessation
- 2002-04-23 EP EP02728893A patent/EP1381604B1/en not_active Expired - Lifetime
- 2002-04-23 KR KR10-2003-7013709A patent/KR20040058111A/en not_active Application Discontinuation
- 2002-04-23 CA CA002444214A patent/CA2444214A1/en not_active Abandoned
-
2003
- 2003-12-19 US US10/739,217 patent/US6946116B2/en not_active Expired - Lifetime
-
2005
- 2005-08-15 US US11/203,429 patent/US7425318B2/en not_active Expired - Lifetime
-
2012
- 2012-07-17 US US13/550,885 patent/USRE44354E1/en not_active Expired - Lifetime
- 2012-07-17 US US13/550,853 patent/USRE44338E1/en not_active Expired - Lifetime
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006469A1 (en) | 1993-08-28 | 1995-03-09 | Cancer Research Campaign Technology Limited | Benzazole compounds for use in therapy |
EP0659418A1 (en) | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | 2-Phenyl-3-azoylbenzothiophene for treating Alzheimer's disease |
US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
WO1997041856A1 (en) | 1996-05-08 | 1997-11-13 | Massachusetts Institute Of Technology | ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) |
WO1998017267A1 (en) | 1996-10-23 | 1998-04-30 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
WO1999024394A2 (en) | 1997-11-06 | 1999-05-20 | University Of Pittsburgh | Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
US6037473A (en) | 1997-11-13 | 2000-03-14 | Haarmann & Reimer Gmbh | Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation |
WO2002085903A2 (en) | 2001-04-23 | 2002-10-31 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US6696039B2 (en) | 2001-04-23 | 2004-02-24 | Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US6946116B2 (en) * | 2001-04-23 | 2005-09-20 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
US7425318B2 (en) * | 2001-04-23 | 2008-09-16 | The Trustees Of The University Of Pennsylvania | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
Non-Patent Citations (59)
Also Published As
Publication number | Publication date |
---|---|
WO2002085903A2 (en) | 2002-10-31 |
US20060051293A1 (en) | 2006-03-09 |
USRE44354E1 (en) | 2013-07-09 |
JP2005512945A (en) | 2005-05-12 |
US7425318B2 (en) | 2008-09-16 |
JP4317955B2 (en) | 2009-08-19 |
WO2002085903A3 (en) | 2003-02-27 |
AU2002258915B2 (en) | 2007-11-15 |
US20030059369A1 (en) | 2003-03-27 |
KR20040058111A (en) | 2004-07-03 |
ATE349446T1 (en) | 2007-01-15 |
CA2444214A1 (en) | 2002-10-31 |
DE60217090D1 (en) | 2007-02-08 |
DE60217090T2 (en) | 2007-07-12 |
EP1381604A2 (en) | 2004-01-21 |
EP1381604B1 (en) | 2006-12-27 |
US6946116B2 (en) | 2005-09-20 |
TWI245764B (en) | 2005-12-21 |
US6696039B2 (en) | 2004-02-24 |
US20040131545A1 (en) | 2004-07-08 |
CN1620454A (en) | 2005-05-25 |
ES2274973T3 (en) | 2007-06-01 |
CN100422180C (en) | 2008-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE44338E1 (en) | Amyloid plaque aggregation inhibitors and diagnostic imaging agents | |
US7250525B2 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
AU2002258915A1 (en) | Amyloid plaque aggregation inhibitors and diagnostic imaging agents | |
EP1999109B1 (en) | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | |
AU2002323417A1 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
US20110158907A1 (en) | Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques | |
US20050271584A1 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |